0232 454 14 14 0232 966 14 14

Prof. Dr. Güner Hayri Özsan

Görev Aldığı Bölümler Hematoloji

Görev Aldığı Lokasyonlar İzmir Tınaztepe Üniversitesi Özel Buca Hastanesi İzmir Tınaztepe Üniversitesi Özel Galen Hastanesi

Profesör Dr. 2008-

Doçent Dr. 2002 -2008

Yardımcı Doçent 1998-2002

Hematoloji Uzmanlığı Dokuz Eylül Üniversitesi 1998

Dahiliye Uzmanlığı Ege Üniversitesi Tıp Fakültesi 1994

Tıp Fakültesi Dokuz Eylül Üniversitesi, 1987

1995-2025 DEU Tıp Fakültesi Hematoloji Bilim Dalı

2002-2021 DEU Kemik İliği Nakli Sorumlusu

2009-2010 MAYO klinik Rochester Konuk Profesör Öğretim Üyesi (Multipl Myelom ve Kemik iliği nakli alanlarında)

2017-2021 TÜRK HEMATOLOJİ DERNEĞİ BAŞKANI

2015-2017 TÜRK HEMATOLOJİ DERNEĞİ Genel Sekreteri

2005-2009 TÜRK HEMATOLOJİ DERNEĞİ Araştırma Sekreteri

1987-1989 Kars Susuz Merkez Sağlık Ocağı

ÖZSAN G. H., Multipl Myelom Tedavisinde IRAK Proteinlerinin Olası Etkilerinin Araştırılması, M. SOĞANCI Devam ediyor

ÖZSAN G. H. Multiple myelom ve böbrek yetmezliği bulunan hastaların, sistemik tedavi sonrası böbrek yetmezliği evrelerine göre reverzibilite ve sağkalım oranı, D. DELİBALTA 2023

ÖZSAN G. H., Multipl myelom ile takip edilen, uzun yaşam süresine ve kısa yaşam süresine sahip hastaların özelliklerinin karşılaştırılması, Tıpta Uzmanlık, İ.ERAY(Öğrenci), 2022

ÖZSAN G. H., Multipl myelom tanılı hastalarda yapılan otolog kök hücre nakli sonrası c-reaktif protein ve engrafman ilişkisi, Tıpta Uzmanlık, G.KÖKCÜ(Öğrenci), 2020

ÖZSAN G. H., ALACACIOĞLU İ., Allojenik kemik iliği nakli yapılan hastalarda CMV DNA antijenemi durumunun değerlendirilmesi, Tıpta Uzmanlık, M. KESKİNKILIÇ(Öğrenci), 2019

ÖZSAN G. H., DEÜ Hastanesi erişkin Hematoloji Bilim Dalında takip edilen hodgkin ve diffüz büyük b hücreli lenfoma hastalarının ara değerlendirme sonuçları ile hastalık prognozu ilişkisi, Tıpta Uzmanlık, E.ERPEK(Öğrenci), 2018

ÖZSAN G. H., Dokuz Eylül Üniversitesi tıp fakültesi hastanesi hematoloji bilim dalı tarafından takip edilen periferal T hücreli lenfoma hastalarının değerlendirilmesi, Tıpta Uzmanlık, S.YASİN GÖKSU,2017

ÖZSAN G. H., Esansiyel trombositoz tanısı ile izlenen hastaların klinik izlemi ve eski risk sınıflama sistemi ile Ipset skorlama sisteminin karşılaştırılması, Tıpta Uzmanlık, S.MERSİN, 2016

ÖZSAN G. H., Otolog kemik iliği transplantasyonunda mobilizasyon başarısız olan hastalarda pleriksafor (AMD3100) etkisi, Tıpta Uzmanlık, N.I. KARAOSMAN, 2016

ÖZSAN G. H., Yaşlıların diffüz büyük b hücreli lenfoması tedavi sonuçları ve etkileyen prognostik faktörler, Tıpta Uzmanlık, S.C. ADIYAMAN 2016

ÖZSAN G. H., Allojenik hematopoetik kök hücre nakli yapılan hastalarda ABO kan grubu uyumsuzluğunun nakil sonuçlarına etkisinin değerlendirilmesi, Tıpta Uzmanlık, D.YILDIZ(Öğrenci), 2016

ÖZSAN G. H., Relaps/refrakter lenfoma hastalarında kurtarma kemoterapi rejimlerinin retrospektif değerlendirmesi, Tıpta Uzmanlık, S.YILMAZ(Öğrenci), 2014

ÖZSAN G. H., Otolog kök hücre nakli yapılan lenfoma hastalarında engraftman dönemindeki mutlak lenfosit sayısının progresyonsuz sağ kalıma etkisi ve rituximab kullanımı ile ilişkisi, Tıpta Uzmanlık, S.TÜMKAYA(Öğrenci), 2012

ÖZSAN G. H., Lösemik kök hücrelerde erken embriyonik kök hücre transkripsiyon faktörlerinin ekspresyonunun araştırılması, Doktora, H.ATEŞ(Öğrenci), 2009

ÖZSAN G. H., Kemik iliğinde fibrozis ve anjiyogenezisin engraftman üzerine etkisi, Tıpta Uzmanlık, N.TURGUT(Öğrenci), 2009

ÖZSAN G. H. Polisitemia Vera'da farklı sitokinler varlığında STI571'in eritroid koloni oluşumuna etkisi, Ö. PİŞKİN, Nisan 2003

ÖZSAN G.H.: Siklooksijenaz-2 (COX2) inhibitörlerinin kronik myeloid lösemi blastik hücre serilerine inhibitör etkisinin araştırılması, F. VURAL, Haziran 2002

ÖZSAN G. H., Hipertiroidi ve hipotiroidide plazma doku faktörü yolu inhibitörü (TFPI) düzeylerinin değerlendirilmesi, Tıpta Uzmanlık, M.A. ÖZCAN2002

page1image56053408

MAKALELER:

Döngelli H, Özsan GH: A case report Cold agglutinin syndrome as a precursor fort he diagnosis of low-grade lymphoma Med Int (Lond) 2024 Dec 18;5
Mehtap Ö, Toptas T, Dal MS, Karadag FK, Atas U, Özsan GH, Sayınalp N, Saydam G, Uçar MA, Kırkızlar HO, Salim O, Tekinalp A, Özkalemkaş F, Pepedi F, Akay OM, Kılıçaslan E, Paydas S, Bozdağ SC, Yılmaz M, Karakus V, Arikan FG, Darçın T, Erdogan E, Cinar E, Gürsoy V, Durusoy SS, Birtaş Ateşoğlu E, Tombak A, Büyükkurt N, Özcan M, Altuntaş F, Kaygusuz Atagündüz I, Ferhanoglu B.: A New Scorring System to Predict Survival in elderly advanced stages Hodgkins Lymphoma Patients. Leuk Lymphoma. 2024 Dec;65(14):2190-2198. doi: 10.1080/10428194.2024.2395458. Epub 2024 Sep 13.
Erdogan Yucel E, Kirmaz AT, Kakci M, Yavuz AF, Sencelikel T, Alacacioglu I, Ozsan GH.: The Effect of Age on High Dose Therapy with Autologous Stem Cell support in Multiple Myeloma: A Single Center Experience. J Clin Med. 2024 Jul 16;13(14):4142. doi: 10.3390/jcm13144142.
Solmaz S, Uzun O, Sevindik OG, Demirkan F, Ozcan MA, Ozsan GH, Alacacıoglu I.: The effect of heamoglobin, albümin, lymphosit and platellet score on the prognosis in patients with Multiple Myeloma. Int J Lab Hematol. 2023 Feb;45(1):13-19. doi: 10.1111/ijlh.13958. Epub 2022 Sep 2.
Civriz Bozdağ S, Cengiz Seval G, Yönal Hindilerden İ, Hindilerden F, Andıç N, Baydar M, Aydın Kaynar L, Toprak SK, Göksoy HS, Balık Aydın B, Demirci U, Can F, Özkocaman V, Gündüz E, Güven ZT, Özkurt ZN, Demircioğlu S, Beksaç M, İnce İ, Yılmaz U, Eroğlu Küçükdiler H, Abishov E, Yavuz B, Ataş Ü, Mutlu YG, Baş V, Özkalemkaş F, Üsküdar Teke H, Gürsoy V, Çelik S, Çiftçiler R, Yağcı M, Topçuoğlu P, Çeneli Ö, Abbasov H, Selim C, Ar MC, Yücel OK, Sadri S, Albayrak C, Demir AM, Güler N, Keklik M, Terzi H, Doğan A, Yegin ZA, Kurt Yüksel M, Sadri S, Yavaşoğlu İ, Beköz HS, Aksu T, Maral S, Erol V, Kaynar L, İlhan O, Bolaman AZ, Sevindik ÖG, Akyay A, Özcan M, Gürman G, Ünal Ş, Yavuz Y, Diz Küçükkaya R, Özsan GH.: Clinical charactheristics and outcomes of COVID-19 in Turkish patients with hematologic malignancies Turk J Hematol 2022 Feb 23 39;1
Beksac M, Seval GC, Kanellias N, Coriu D, Rosiñol L, Ozet G, Goranova-Marinova V, Unal A, Bila J, Ozsan H, Ivanaj A, Balić LI, Kastritis E, Bladé J, Dimopoulos MA : A Real Multicenter retrospective Study on Extramedullary Disease From Balkan Myeloma Study Group and Barcelona University : Analysis of parameters that Improve Outcome. .Haematologica. 2021 Apr 1;106(4):1228. doi: 10.3324/haematol.2020.278272.
Şeyhanlı A, Yavuz B, Akşit Z, Yüce Z, Özkal S, Altungöz O, Demirkan F, Alacacıoğlu İ, Özsan GH, "Assessment of Bone Marrow Biopsy and Cytogenetic Findings in Patients with Multiple Myeloma", Turkish Journal of Hematology, 2021 Nov 26, 2021, Araştırma(Research) Makale, Ulusal Hakemli, Doçentlik sonrası
Şeyhanlı A, Özkan YC, Bengi G, Alacacıoğlu İ, Özsan GH, Demirkan F, "Evaluation of using fresh frozen plasma for patients with cirrhosis at a tertiary healthcare center in Turkey: Strict transfusion policies are essential.", Transfusion and apheresis science, 2021, 2021, Araştırma(Research) Makale, SCI-Expanded, Doçentlik sonrası
Şeyhanlı A, Selimoğlu İ, Alacacıoğlu İ, Demirkan F, Özsan GH, "Guillain Barré Syndrome in a Multiple Myeloma Patient After the Autologous Transplantation: A Case Report", Akdeniz Tıp Dergisi, 7,3,479-482, 2021, Olgu Sunumu, ULAKBİM, Doçentlik sonrası

Şeyhanlı A, Yavuz B, Selimoğlu İ, Şengün İŞ, Aslan AT, Özsan GH, Alacacıoğlu İ, Demirkan F, "Therapeutic plasma exchange in neurological disaeses: Eleven years experience at a tertiary care center in Turkey.", therapeutic apheresis and dialysis, 25 march 2021, 2021, Araştırma(Research) Makale, SCI-Expanded, Doçentlik sonrası
Baykal Köse S, Eda Açıkgöz, Ahmet Sinan Yavuz,, Öykü Gönül Geyik,, Ateş H, Osman Uğur Sezerman, Özsan GH, Yüce Z, "Adaptive phenotypic modulations lead to therapy resistance in chronic myeloid leukemia cells", 2020; 15(2): e0229104., 2020; 15(2): e0229104., 2020, Araştırma(Research) Makale, SCI-Expanded, Doçentlik sonrası
Mutlu U, Balcı A, Özsan GH, Özkal S, Şeyhanlı A, Özgül HA, "Computed tomography characteristics of multiple myeloma and other osteolytic metastatic bone lesions", Acta Radiologica, Acta Radiologica. December 2020., 2020, Araştırma(Research) Makale, SCI-Expanded, Doçentlik sonrası
Mutlay F, Sevindik ÖG, Solmaz Medeni Ş, Acar C, Alp Çavuş S, Şeyhanlı A, Özcan MA, Demirkan F, Özsan GH, Ündar B, Alacacıoğlu İ, "Akut Miyeloid Lösemi Tanılı Hastalarda Remisyon İndüksiyon Kemoterapisi Döneminde Primer Antifungal Profilaksi Alan ve Almayan Hastaların Retrospektif Olarak Değerlendirilmesi", Lösemi Lenfoma Myelom Dergisi, 2020;4(1):1-9, 2020, Araştırma(Research) Makale, Ulusal Hakemli, Doçentlik sonrası
Adıyaman SC, Alacacıoğlu İ, Erşen Danyeli A, Türkyılmaz D, Sevindik ÖG, Demirkan F, Pişkin Ö, Özcan MA, Ündar B, Özkal S, Özsan GH, "Prognostic Factors in Elderly Patients with Diffuse Large B- Cell Lymphoma and their treatment results", Turkish Journal of Haematology, 2019, Mayıs;36(2):81-87, 2019, Araştırma(Research) Makale, SCI-Expanded, Doçentlik sonrası
solmaz s, türkyılmaz d, acar c, sevindik g, Yüksel F, Pişkin Ö, Özcan MA, Demirkan F, Ündar B, Alacacıoğlu İ, Özsan GH, "Does Reinfusion of Stem Cell Products on Multiple Days Affect Engraftment?", Turkish Journal of Hematology, 2018 Nov 13;35(4):271-276, 2018, Araştırma(Research) Makale, SCI-Expanded, Doçentlik sonrası
solmaz s, kahraman s, sevindik g, acar c, türkyılmaz d, Alacacıoğlu İ, Pişkin Ö, Özcan MA, Özsan GH, Ündar B, Demirkan F, "A Comparison of Fresenius Com.Tec Cell and Spectra Optia Cell Separators for Autologous and Allogeneic Stem Cell Collections: Single Center Experience.", İndian journal of hematology and blood transfusion, 2018 Oct;34(4):677-683., 2018, Araştırma(Research) Makale, SCI- Expanded, Doçentlik sonrası
ŞERİFE SOLMAZ, O UZUN, C ACAR, G SEVİNDİK, Pişkin Ö, Özsan GH, Demirkan F, Ündar B, ALACACIOĞLU A, Özcan MA, Alacacıoğlu İ, "Is the platelet-to-lymphocyte ratio a new prognostic marker in multiple myeloma?", Journal of Laboratory Physicians, 2018 Oct-Dec;10(4):363-369, 2018, Araştırma(Research) Makale, ESCI, Doçentlik sonrası
solmaz s, acar c, olgun a, acar a, seyhanlı a, taskıran e, sevindik g, Alacacıoğlu İ, Pişkin Ö, Özcan MA, Demirkan F, Ündar B, Özsan GH, "Can Neutrophil-to-Lymphocyte Ratio, Monocyte-to- Lymphocyte Ratio, and Platelet-to-Lymphocyte Ratio at Day +100 be used as a prognostic marker in Multiple Myeloma patients with autologous transplantation?", Clinical Transplantation, 2018 Sep;32(9):e13359, 2018, Araştırma(Research) Makale, SCI-Expanded, Doçentlik sonrası
Ünlü M, Özsan GH, Sarıoğlu S, "The Scope of Kidney Affection in Monoclonal Gammopathies at All Levels of Clinical Significance", Turkish Journal of Hematology, Dec 1;34(4):282-288., 2017, Derleme(Review) Makale, SCI-Expanded, Doçentlik sonrası
Nurhilal Büyükkurt, Güner Hayri Özsan, Sermin Özkal, Gülşah Şeydaoğlu, İnci Alacacıoğlu, Mehmet Ali Özcan, Fatih Demirkan, Özden Pişkin, Bülent Ündar, "Effects of bone marrow fibrosis and angiogenetic structure on autologous hematopoietic stem cell engraftment Kemik iliği fibrozis ve anjiogenezisinin hematopoetik kök hücre engraftmanı üzerine etkisi", Cukurova Medical Journal, 42 (3): 499-506 /2017, 2017, Araştırma(Research) Makale, ESCI, Doçentlik sonrası
Karaman A, Solmaz Medeni Ş, Sevindik ÖG, Acar C, Kahraman S, Tunalı S, Alacacıoğlu İ, Altungöz O, Pişkin Ö, Demirkan F, Özsan GH, Özcan MA, "KRONİK MYELOİD LÖSEMİ TANILI HASTALARIMIZIN RETROSPEKTİF DEĞERLENDİRİLMESİ", DEÜ Tıp Fakültesi Dergisi, CİLT30,SAYI3,ARALIK2016,103-112, 2016, Araştırma(Research) Makale, Ulusal Hakemli, Doçentlik sonrası
Kahraman S, Alp Çavuş S, Turgut N, Özcan MA, Yapar N, Pişkin Ö, Demirkan F, Özsan GH, Ündar B, "350 Febrile Neutropenia Episodes of 156 Patients With Hematological Malignancies;Single Center Experience", Klinik Tıp Bilimleri, 4(6):24-30, 2016, Araştırma(Research) Makale, Ulusal Hakemli, Doçentlik sonrası

Baran Şen, Serkan Güler, Berivan Çeçen, Kumtepe Erdem, Hüsnü Alper Bağrıyanık, Sermin Özkal, Mehmet Ali Özcan, Güner Hayri Özsan, Namık Şanlı, Mehmet Hasan Tatari, "The Effect of Autologous Platelet Rich Plasma in the Treatment of Achilles Tendon Ruptures: an Experimental Study on Rabbits.", Balkan Medical Journal, 33/1/94-101, 2016, Araştırma(Research) Makale, SCI-Expanded
Solmaz Medeni Ş, Sevindik ÖG, Acar C, Türkyılmaz D, Yiğit Kaya S, Tunalı S, Alacacıoğlu İ, Pişkin
Ö, Demirkan F, Özsan GH, Özcan MA, Ündar B, "AKUT MYELOİD LÖSEMİ HASTALARIMIZIN RETROSPEKTİF DEĞERLENDİRİLMESİ", DEÜ Tıp Fakültesi Dergisi, CİLT29,SAYI2,(AĞUSTOS2015),65-69, 2015, Araştırma(Research) Makale, Ulusal Hakemli, Doçentlik sonrası
Büyükkurt N, Özcan MA, Ergene Ü, Payzın B, Tunalı S, Demirkan F, Özsan GH, Pişkin Ö, Ündar B, "The Effect of Fc?RIIIA Gene Polymorphism on the Treatment of Diffuse Large B-cell Non-Hodgkin Lymphoma: A Multicenter Prospective Observational Study.", Turk J.Haematol., 2015 Jun;32(2):152-7. doi: 10.4274/tjh.2013.0367., 2015, Araştırma(Research) Makale, SCI, Doçentlik sonrası
Omur Gokmen Sevindik, Sinan Mersin, Abdullah Katgi, Sunay Tunalı, Serife Medeni Solmaz, Celal Acar, Inci Alacacioglu, Ozden Piskin, Mehmet Ali Ozcan, Fatih Demirkan, Bulent Undar, Guner Hayri Ozsan, "IPSET-Thrombosis better identifies thrombosis free survival: a turkish cohort", Clinical Lymphoma, Myeloma and Leukemia, http://dx.doi.org/10.1016/j.clml.2015.02.004, 2015, Araştırma(Research) Makale, SCI-Expanded (1 eserde atıf), Doçentlik sonrası
Omur Gokmen Sevindik, Zeynep Guc, Selda Kahraman, Serife Medeni Solmaz, Abdullah Katgı, Celal Acar, Inci Alacacioglu, Ozden Piskin, Guner Hayri Ozsan, Fatih Demirkan, Bulent Undar, Mehmet Ali Ozcan, "Hypoalbuminemia is a surrogate biomarker of poor prognosis in myelodysplastic syndrome even when adjusted with comorbidities", Leukemia and Lymphoma, 10.3109/10428194.2015.1014362, 2015, Araştırma(Research) Makale, SCI-Expanded (3 eserde atıf), Doçentlik sonrası
Ömür Gökmen Sevindik, İnci Alacacıoğlu, Abdullah Katgı, Şerife Medeni Solmaz, Celal Acar, Özden Pişkin, Mehmet Ali Özcan, Fatih Demirkan, Bülent Ündar, Güner Hayri Özsan, "Renal and Neurological Response with Eculizumab in a Patient with Transplant Associated Thrombotic Microangiopathy after Allogeneic Hematopoietic Progenitor Cell Transplantation", Case Reports in Hematology, 2015, 2015, Olgu Sunumu, Yurtdışı Hakemli, Doçentlik sonrası
Solmaz Medeni Ş, Füsun Özdemirkıran, Kadriye Bahriye Payzın, Sevindik ÖG, Acar C, Türkyılmaz D, Yiğit Kaya S, Alacacıoğlu İ, Pişkin Ö, Demirkan F, Özsan GH, Özcan MA, "Paroksismal Nokturnal Hemoglobinürili Olguların Değerlendirilmesi: İki Merkezin Deneyimi", Dokuz Eylül Üniversitesi Tıp Fakültesi Dergisi, cilt 28, sayı 3,Aralık 2014, 2014, Araştırma(Research) Makale, Ulusal Hakemli, Doçentlik sonrası
Alacacıoğlu İ, Solmaz Medeni Ş, Özsan GH, Payzin B, Sevindik ÖG, Acar C, Katgı A, Özdemirkan F, Pişkin Ö, Özcan MA, Ündar B, Demirkan F, "Is the BFM Regimen Feasible for the Treatment of Adult Acute Lymphoblastic Leukemia? A Retrospective Analysis of the Outcomes of BFM and Hyper-CVAD Chemotherapy in Two Centers", Chemotherapy, 2014;60:211-218, 2014, Araştırma(Research) Makale, SCI (10 eserde atıf), Doçentlik sonrası
Katgı A, Sevindik ÖG, Gökbulut AA, Özsan GH, Yüksel F, Solmaz SM, Alacacıoğlu İ, Özcan MA, Demirkan F, Baran Y, Pişkin Ö, "Nilotinib does not alter the secretory functions of carotid artery endothelial cells in prothrombotic or antithrombotic fashion", Clin Appl Thromb Hemost, Epub 2014, 2014, Araştırma(Research) Makale, SCI-Expanded (7 eserde atıf), Doçentlik sonrası
Cehreli C, Alacacıoğlu İ, Pişkin Ö, Ateş H, Çehreli R, Çalıbaşı G, Yüksel E, Özkal S, Özsan GH, "Mast cell leukemia associated with undefined morphology and chronic basophilic leukemia.", BMC Hematology, 14(1):17, 2014, Olgu Sunumu, Yurtdışı Hakemli, Doçentlik sonrası
Turan MO, Özsan GH, Dicle O, Akkoçlu A, "Case reports in internal medicine 2014: 1(2): 183-86", Case Reports in Internal Medicine, 2014:1(2):183-86, 2014, Araştırma(Research) Makale, SCI-Expanded, Doçentlik sonrası
Serife M. SOLMAZ, Omur G. SEVINDIK, Celal ACAR, Inci ALACACIOGLU, Ozden PISKIN, Guner H. OZSAN, Bulent UNDAR, Fatih DEMIRKAN, M. ALI OZCAN, "Disseminated Fusarium Infection in an Acute Lymphoblastic Leukemia (ALL) Patient after Allogeneic Bone Marrow Transplantation", Uluslararası Hematoloji-Onkoloji Dergisi, 2013, Vol 23, Num 3 (Special Issue) Page(s): 013-015, 2013, Editöre Mektup, SCI-Expanded, Doçentlik sonrası

Omur G. SEVINDIK, Serife M. SOLMAZ, Celal ACAR, İnci ALACACIOGLU, Ozden PISKIN, Güner H. OZSAN, Bulent UNDAR, Fatih DEMIRKAN, M. Ali OZCAN, "Management of IFI in Febrile Neutropenic Patients: A Case of Invasive Aspergillosis Treated with Liposomal Amphotericin B", Uluslararası Hematoloji-Onkoloji Dergisi, 2013, Vol 23, Num 3 (Special Issue), 2013, Editöre Mektup, SCI- Expanded, Doçentlik sonrası
Akman T, Pişkin Ö, Özcan MA, Alacacıoğlu İ, Özsan GH, Demirkan F, Ündar B, "Primer iskelet kası lenfoması olan iki olgu ve literatür derlemesi", Dokuz Eylül Üniversitesi Tıp Fakültesi Dergisi, 3/151- 155/2013, 2013, Olgu Sunumu, Ulusal Hakemli, Doçentlik sonrası
Katgı A, Ataca P, Kahraman S, Sevindik ÖG, Sönmez Ü, SM Solmaz, Pişkin Ö, Demirkan F, Özsan GH, "Successful hematopoietic engraftment with gray platelets after allogeneic hematopoietic stem cell transplantation from gray platelet syndrome donor.", Blood Coagul Fibrinolysis., 2013 Mar;24(2):208- 10., 2013, Olgu Sunumu, SCI, Doçentlik sonrası
Kahraman S, Ataca P, Katgı A, Pişkin Ö, Özkal S, Özcan MA, Özsan GH, Demirkan F, Ündar B, "KMML Hastasında Santral Sinir Sisteminde Gelişen yeloid Sarkom ve AML'ye Dönüşüm", Dokuz Eylül üniversitesi tıp fakültesi dergisi, 26/2/131-135/2012, 2012, Araştırma(Research) Makale, Ulusal Hakemli, Doçentlik sonrası
Malgir O, Kahraman S, Katgı A, Pişkin Ö, Sevindik ÖG, Özcan MA, Özsan GH, Demirkan F, Ündar B, "İmmün Trombositopenili Hastaların Klinik Seyir ve Tedavi Cevabı Yönünden Değerlendirmesi; Tek Merkez Deneyimi", Dokuz Eylül Üniversitesi Tıp Fakültesi Dergisi, 26/3/159-164/2012, 2012, Araştırma(Research) Makale, Ulusal Hakemli, Doçentlik sonrası
Katgı A, Kahraman S, Ataca P, Pişkin Ö, Özcan M, Özsan G, Demirkan F, Ündar B, "Occurence in a case of phledelphia Negative Acute Lymphoblastic leukemia foolowing Treatment for Ewing's Sarcoma", Marmara Medical Journal, 2012;25:100-2, 2012, Olgu Sunumu, Ulusal Hakemli, Doçentlik sonrası
Güner Hayri ÖZSAN, "Hodgkin Lenfoma", Türkiye klinikleri hematoloji onkoloji, cilt 5 sayı 3 sayfa 13- 19 yıl 2012, 2012, Derleme(Review) Makale, Ulusal Hakemli, Doçentlik sonrası
Katgı A, Olgun A, Kahraman S, Pişkin Ö, Özcan MA, Özsan GH, Demirkan F, Ündar B, "Tek Merkez Deneyimi:Folliküler Lenfomalı Olgularımızın Retrospektif Değerlendirmesi", Dokuz Eylül Üniversitesi Tıp Fakültesi Dergisi, cilt 26, sayı 1, (nisan) 2012, 21-26, 2012, Araştırma(Research) Makale, Ulusal Hakemli, Doçentlik sonrası
Demir V, Kahraman S, Katgı A, Pişkin Ö, Özsan GH, Demirkan F, Ündar B, Özcan MA, "Kronik Lenfositik Lösemi Hastalarının Genel Klinik Değerlendirilmesi", Dokuz Eylül Üniversitesi Tıp Fakültesi Dergisi, cilt 26,sayı 1, (nisan) 2012, 9-19, 2012, Araştırma(Research) Makale, Ulusal Hakemli, Doçentlik sonrası
Aktan Ş, Akarsu S, Avcı C, Lebe B, Katgı A, Özsan G, "Dissemine granüloma anulare ve asemptomatik multipl myelom birlikteliği", Türkderm, 47(3)/ 176-179/ 2013, 2012, Olgu Sunumu, SCI- Expanded, Doçentlik sonrası
Özsan GH, Micallef IN, Dispenzieri A, Kumar S, Lacy MQ, Dingli D, Hayman SR, Buadi FK, Wolf RC, Gastineau DA, Hogan WJ, Gertz MA, "hematopoietic recovery kinetics predicts for poor cd34+ cell mobilization after cyclophosphamide chemotherapy in multiple myeloma", american journal of hematology, 87(1):1-4 2012 doi:10.1002/ajh.22179 epub 2011 sep. 29, 2012, Araştırma(Research) Makale, SCI (8 eserde atıf), Doçentlik sonrası
Katgı A, Ataca P, Kahraman S, Pişkin Ö, Özcan M, Demirkan F, Özsan G, Ündar B, "Ischemic stroke after recombinant factor VIIa treatment in acquired hemophilia A patient.", BLOOD COAGULATION AND FIBRINOLYSIS, Blood Coagul Fibrinolysis. 2011 Nov 24. [Epub ahead of print], 2011, Olgu Sunumu, SCI-Expanded, Doçentlik sonrası
Güner Hayri ÖZSAN, "Otolog kök hücre transplantasyonunun hematolojik malignansilerin tedavisindeki yeri", Hematolog, cilt:1 sayı:1 S:217-229, 2011, 2011, Derleme(Review) Makale, Ulusal Hakemli, Doçentlik sonrası
Katgı A, Başoğlu T, Kahraman S, Pişkin Ö, Özcan M, Özsan G, Demirkan F, Ündar B, "Tek Merkez Deneyimi: Relaps/ Refrakter Akut Lösemi ve Lenfomalı Olgularda Ida-FLAG Kemoterapisi", DEÜ Tıp Fakültesi Dergisi, 25/2/93-98/mayıs 2011, 2011, Araştırma(Research) Makale, Ulusal Hakemli, Doçentlik sonrası
Katgı A, Kahraman S, Ataca P, Pişkin Ö, Özcan M, Özsan G, Demirkan F, Ündar B, "Malign pleural Effusion In A Patient With Multiple Myeloma", Dokuz Eylül üniversitesi tıp fakültsi edrgisi, 25/1/43-

Kahraman S, Ünal S, Sevgen Z, Katgı A, Pişkin Ö, Özcan M, Özsan G, Demirkan F, Ündar B, "Periferik Hematopoetik Kök Hücre Nakli Yapılan Lenfoma Hastalarımız; Tek Merkez Deneyimi", DEÜ Tıp Fakültesi Dergisi, Cilt:25/Sayı:1/Sayfa:25-30/Yıl:2011, 2011, Araştırma(Research) Makale, Ulusal Hakemli, Doçentlik sonrası
Mistry PK, Cappellini MD, Lukina E, Özsan H, Mach Pascual S, Rossenbaum H, Helena Solano M, Spigelman Z, Villarrubia J, Watman NP, Massenkeil G, "A reapraisal of gaucher disease-diagnosis and disease management algorithms", american journal of hematology, 86(1):110-115 2011, 2011, Derleme(Review) Makale, SCI (36 eserde atıf), Doçentlik sonrası
Özsan GH, Dispenzieri A, "serum free light chain analysis in multiple myeloma and plasma cell dyscrasias", expert review of clinical immunology, 7(1):65-73 2011, 2011, Derleme(Review) Makale, Index Meducus, Doçentlik sonrası
Alacacıoğlu İ, Kargi A, Özcan M, Pişkin Ö, Solak C, Seçil M, UNLU M, Demirkan F, Özsan G, Ündar B, "Fatal disseminated mucormycosis in a patient with mantle cell non-Hodgkin's lymphoma: an autopsy case.", Brazilian of journal infectious disease, 2009 Jun;13(3):238-41, 2009, Olgu Sunumu, SCI- Expanded (9 eserde atıf), Doçentlik sonrası
Alacacıoğlu İ, Turgut N, Pişkin Ö, Özcan M, Demirkan F, Özsan G, Ündar B, "Multipl myeloma presenting as massive ascites", Journal of BUON, 14, 307-308 (2009), 2009, Olgu Sunumu, SCI- Expanded, Doçentlik sonrası
Alacacioglu I, Özcan M, Özkal S, Pişkin Ö, Turgut N, Demirkan F, Özsan G, Kargı H, Ündar B, "Prognostic significance of immunohistochemical classification of diffuse large B-cell lymphoma", Hematology, 14(2):84-9, 2009, 2009, Araştırma(Research) Makale, SCI-Expanded (26 eserde atıf), Doçentlik sonrası
Sariosmanoglu N, Ugurlu B, Turgut NH, Demirkan F, Ozsan H, Ergor G, Gulay Z, Hazan E, Oto O, "use of tunnelled catheters in haematological malignancy patients with neutropenia.", the journal of international medical research, 36 (5), 1103-1111, 2008, 2008, Araştırma(Research) Makale, SCI- Expanded, Doçentlik sonrası
Dr. G. Hayri Özsan, Dr. Özden Pişkin, "Yetişkin kök hücre biyolojisi", Türkiye klinikleri, 1/2/10-15, 2008, Derleme(Review) Makale, Ulusal Hakemli, Doçentlik sonrası
Demirkan F, Alacacıoğlu İ, Pişkin Ö, Özsan GH, Özcan MA, Ündar B, "Prognostic factors and scoring systems in chronic myelomonocytic leukemia: A retrospective analysis of 37 patients", Uluslararası Hematoloji Onkoloji Dergisi, 2008,18(4):193-200, 2008, Araştırma(Research) Makale, Ulusal Hakemli, Doçentlik sonrası
Aydan Çelebiler Çavuşoğlu, Saydam S, Mehmet Alakavuklar, Canda T, Sevinç A, Kılıç Y, Harmancıoğlu İÖ, Koçdor MA, Kınay AM, Hilmi Alanyalı, Görken İ, Balcı P, Demirkan HMB, Sakızlı M, Özsan G, "A pilot study for human tumor/DNA banking:returned more questions than answers", MEDICAL ONCOLOGY, 25/471-73/2008, 2008, Araştırma(Research) Makale, SCI-Expanded (6 eserde atıf), Doçentlik sonrası
Piskin O, Alacacioglu I, Ozkal S, Ozcan MA, Demirkan F, Hayri Ozsan G, Kargi A, Undar B, "A patient with diffuse large B-cell non-Hodgkin's lymphoma and AA type amyloidosis", J BUON, 13(1):113-6, 2008, 2008, Olgu Sunumu, SCI-Expanded (9 eserde atıf), Doçentlik sonrası
Ozcan M, Akar S, Alacacıoğlu İ, Pişkin Ö, Yüksel F, Gürler O, Akkoç N, Demirkan F, Özsan G, Özkan S, Önen F, Ündar B, "Plasma Thrombin Activatable Fibrinolysis Inhibitor Levels in Behçet's Disease", Turk J Med Sci, 2007; 37 (5): 267-271, 2007, Araştırma(Research) Makale, SCI-Expanded (2 eserde atıf), Doçentlik sonrası
İnci ALACACIOĞLU, Mehmet A. ÖZCAN, Özden PİŞKİN, Fatih DEMİRKAN, Güner H. ÖZSAN, Bülent ÜNDAR, "Myelomatous effusion in plasma-cell leukemia: a case report", Uluslararası Hematoloji-Onkoloji Dergisi, 3 (17):163-166, 2007, Olgu Sunumu, Ulusal Hakemli, Doçentlik sonrası
Alacacıoğlu İ, Özcan M, Meral M, Pişkin Ö, Demirkan F, Özsan G, Özkal S, Ündar B, "Primer Gastrointestinal Lenfoma Hastalarının Klinik Özellikleri ve Tedavi Sonuçları: Tek Merkez Deneyimi", Uluslararası Hematoloji-Onkoloji Dergisi, 3(17):143-150, 2007, 2007, Araştırma(Research) Makale, SCI-Expanded, Doçentlik sonrası

Alacacıoğlu İ, Özcan M, Pişkin Ö, Demirkan F, Özsan G, Ündar B, "Myelomatous Effusion in Plasma- cell Leukemia: A Case Report", International Journal of Hematology and Oncology, 17 (3), 163-166 (2007)., 2007, Olgu Sunumu, SCI-Expanded, Doçentlik sonrası
FATIH DEMIRKAN, INCI ALACACIOĞLU, OZDEN PISKIN, G. HAYRI OZSAN, BARIS AKINCI, M. ALI OZCAN, TUGBA YAVUZSEN, Uzm.Dr. Erdinç YÜKSEL, BULENT UNDAR, "The clinical, haematological and morphological profile of patients with myelodysplastic syndromes: A single institution experience from Turkey.", Leukemia& Lymphoma, Leuk Lymphoma 48(7):1372-1378, 2007, Araştırma(Research) Makale, SCI-Expanded (10 eserde atıf), Doçentlik sonrası
İnci ALACACIOĞLU, Mehmet Ali ÖZCAN, Özden PİŞKİN, Uzm. Faize YÜKSEL, Ahmet ALACACIOĞLU, Fatih DEMİRKAN, Güner Hayri ÖZSAN, Mehmet POLAT, Yiğit Özgenç, Bülent ÜNDAR, "Increased concentration of soluble CD40 ligand in preeclampsia.", Clinical and Applied Thrombosis/ Hemostasis, Clin Appl Thromb Hemost 13(2):201-205, 2007, Araştırma(Research) Makale, SCI (15 eserde atıf), Doçentlik sonrası
Özden Pişkin, M. Ali Özcan, G. Hayri Özsan, Halil Ateş, Fatih Demirkan, İnci Alacacıoğlu, Bülent Ündar, "Synergistic Effect Of Imatinib Mesylate And Fludarabine Combination On Philadelphia Chromosome Positive Chronic Myelogeneus Leukemia Cell Lines", Turkish Journal of Haematology, Turk J Haematol 24 (1): 23-27, 2007, Araştırma(Research) Makale, Ulusal Hakemli (15 eserde atıf), Doçentlik sonrası
G. Hayri Özsan, "Akut lenfoblastik lösemi", Türkiye Klinikleri Dahili Tıp Bilimleri Hematoloji-Onkoloji Dergisi, Cilt 3, sayı 2, sayfa20-22, yıl 2007, 2007, Derleme(Review) Makale, Ulusal Hakemli, Doçentlik sonrası
Akar S, Ozcan MA, Ates H, Gurler O, Alacacioglu I, Ozsan H, Akkoc N, Ozkan S, Demirkan F, Onen F, "Circulated activated platelets and increased platelet reactivity in patients with Behcet's disease", Clinical and Applied Thrombosis Hemostasis, Clin Appl Thromb Hemost 12 (4): 451-457, 2006, Araştırma(Research) Makale, SCI-Expanded (46 eserde atıf), Doçentlik sonrası
Özden Pişkin, Güner Hayri Özsan, Halil Ateş, Mehmet Ali Özcan, Fatih Demirkan, İnci Alacacıoğlu, Bülent Ündar, "The Effect Of Imatinib Mesylate On The Erythroid Colony Formation From Patients With Polycythemia Vera in The Presence Of Different Cytokines", Turkish Journal of Haematology, Turk J Haematol 23 (3): 136-141, 2006, Araştırma(Research) Makale, Ulusal Hakemli, Doçentlik sonrası
Mehmet Ali Özcan, Mesut Akarsu, Fatih Demirkan, Hale Akpınar, Faize Yüksel, Güner Hayri Özsan, Bülent Ündar, Özden Pişkin, İnci Alacacıoğlu, "Plasma levels of thrombin activatable fibrinolysis inhibitor antigen in active and inactive inflammatory bowel disease", Turkish Journal of Haematology, Turk J Haematol 23 (2): 94-99, 2006, Araştırma(Research) Makale, Ulusal Hakemli (1 eserde atıf), Doçentlik sonrası
MA OZCAN, I ALACACIOGLU, O PİSKİN, B LEBE, N TURGUT, S KAHRAMAN, F DEMİRKAN, GH OZSAN, B UNDAR, "Bortezomib-induced skin lesion", Acta Haematologica, Acta Haematol 116(3):226- 227, 2006, Olgu Sunumu, SCI (7 eserde atıf), Doçentlik sonrası
Alacacıoğlu İ, Pişkin Ö, Bahçeli S, Arıkan G, Özcan M, Demiral A, Özsan G, Demirkan F, Tüzel T, Öztürk AT, Ündar B, "Akut Lenfoblastik Lösemide İzole Optik Sinir Tutulumu: Olgu Sunumu", Dokuz Eylül Üniversitesi Tıp Fakültesi Dergisi, 19 (3), 181-184 (2005), 2005, Olgu Sunumu, ULAKBİM, Doçentlik sonrası
I ALACACIOGLU, MA OZCAN, N KOCAK, A DEMİRAL, O PİSKİN, F DEMIRKAN, GH OZSAN, A SAATCI, B UNDAR, "Bilateral primary orbital non-Hodgkin's lymphoma in a patient with scleroderma: a case report", Leukemia Lymphoma, 46(8):1239-1242, 2005, Olgu Sunumu, SCI-Expanded (5 eserde atıf), Doçentlik sonrası
FILIZ VURAL, MEHMET ALI OZCAN, GÜNER HAYRI OZSAN, HALIL ATES, FATIH DEMIRKAN, OZDEN PISKIN, BULENT UNDAR, "Cyclo-oxygenase 2 inhibitor, nabumetone, inhibits proliferation in chronic myeloid leukemia cell lines.", Leukemia & Lymphoma, Leuk Lymphoma 46(5): 753-756, 2005, Araştırma(Research) Makale, SCI-Expanded (6 eserde atıf), Doçentlik sonrası
I ALACACIOGLU, MA OZCAN, O PİSKİN, F DEMIRKAN, GH OZSAN, B UNDAR, "Chronic Myeloid Leukemia Associated With Extreme Thrombocytosis.", Aqua Haema, 8(4):701-703, 2005, Olgu Sunumu, Yurtdışı Hakemli (2 eserde atıf), Doçentlik sonrası
I ALACACIOGLU, MA OZCAN, A ALACACİOGLU, M POLAT, F YUKSEL, F DEMİRKAN, O PİSKİN, Y ÖZGENÇ, GH OZSAN, B UNDAR, "Plasma levels of thrombin activatable fibrinolysis inhibitor in normal and pre-eclamptic pregnant women", Thrombosis Research, Thromb Res 114(3):155-159,

2004, Araştırma(Research) Makale, SCI (22 eserde atıf), Doçentlik sonrası

MA OZCAN, O PİSKİN, I ALACACIOGLU, Y SAVRAN, GH OZSAN, "İmages in Haematology",
Turkish Journal of Haematology, Turkish Journal of Haematology 2004, 10;1:49., 2004, Ulusal Hakemli, Doçentlik sonrası
MA OZCAN, O PISKIN, I ALACACIOGLU, Y SAVRAN, GH OZSAN, "Images in Haematology", Turkish Journal of Haematology, 21/1/49/2004, 2004, Yorum, SCI-Expanded, Doçentlik sonrası
U YILMAZ, I OZTOP, A YAREN, H ATEŞ, I ALACACIOGLU, GH OZSAN, "Tamoksifenin Plazma Doku Faktörü Düzeyi Üzerine Etkisi.", ADÜ Tıp Fakültesi Dergisi, ADÜ Tıp Fakültesi Dergisi 2004; 5(2):15- 18., 2004, Araştırma(Research) Makale, Ulusal Hakemli, Doçentlik sonrası
Mehmet Ali Özcan, İnci Alacacıoğlu, Barış Akıncı, A. Arzu Sayıner, Müjde Soytürk, Güner Hayri Özsan, Fatih Demirkan, Bülent Ündar, "Akut Lenfoblastik Lösemide Varicella Hepatit Enfeksiyonu", Dokuz Eylül Tıp Dergisi, 18 (2); 173-176, 2004, Olgu Sunumu, Ulusal Hakemli, Doçentlik sonrası
FILIZ VURAL, MEHMET ALI OZCAN, G.HAYRI OZSAN, FATIH DEMIRKAN, OZDEN PISKIN, HALIL ATES, AYDANUR KARGI, BULENT UNDAR, "Gingival involvement in a patient with CD56+ chronic myelomonocytic leukemia", Leukemia& Lymphoma, Leuk Lymphoma 45 (2): 415-418, 2004, Olgu Sunumu, SCI-Expanded (17 eserde atıf), Doçentlik sonrası
Özcan M.Ali, Çömlekçi A, Demirkan F, Yüksel F, Sarı İ, Demir T, Özsan G, Örük G, Yeşil S, Ündar B, "Plasma levels of free tissue factor pathway inhibitor in patients with various thyroid disorders", Thrombosis Research, 110//243-247/2003, 2003, Araştırma(Research) Makale, SCI (39 eserde atıf), Doçentlik sonrası
G. Hayri Özsan, Mehmet Ali Özcan, Serra Menekay, İlhan Öztop, Fatih Demirkan, Meral Fadıloğlu, Bülent Ündar, "Granülosit kolonistimülan faktör (G-CSF) kullanımına bağlı LDH yüksekliği ve LDH izoenzim profili", DEU Tıp Fakültesi Dergisi, 17 (1): 43-48, 2003, Araştırma(Research) Makale, Ulusal Hakemli, Doçentlik sonrası
Doç.Dr. Fatih DEMİRKAN, Doç.Dr. Güner Hayri ÖZSAN, Doç.Dr. Mehmet Ali ÖZCAN, Dr.Filiz Vural, Doç.Dr. İlhan ÖZTOP, Uzm.Dr. Erdinç YÜKSEL, Prof.Dr. Bülent ÜNDAR, "Refractory Thrombocytopenia with Multilineage Dysplasia: A rare Type of Myelodysplastic Syndrome", Turkish Journal of Haematology, Turk J Hematol 20(1):25-30, 2003, Araştırma(Research) Makale, Ulusal Hakemli, Doçentlik sonrası
Vural F, Demirkan F, Özsan G, Kargı H, Cabuk M, Özcan M, Sayan M, Özkal S, Cehreli C, Ündar B, "EBV-associated nasal-type T/natural killer cell lymphoma presenting with polyserositis and rhabdomyolysis", Leukemia&Lymphoma, Leuk Lymphoma 43 (9):1859-1863, 2002, Olgu Sunumu, SCI-Expanded (1 eserde atıf), Doçentlik sonrası
Badak O, Guneri S, Kirimli O, Goldeli O, Aslan O, Ozsan H, "Primary stenting in a patient with acute myocardial infarction and primary antiphospholipid syndrome.", The Journal of Invasive Cardiology, 2002;14(4):194-7., 2002, Derleme(Review) Makale, Index Meducus (7 eserde atıf), Tıpta Uzmanlık sonrası
Akarsu M., Tankurt E., Tunca M., Ozsan H., Tutucu K.N., Ormen M., Onvural B., "Alanine aminotransferase deficiency in a hepatitis B surface antigen positive patient presenting with acute hepatitis.", The Turkish Journal of Gastroenterology, 13(1): 60-2 2002, 2002, Olgu Sunumu, Ulusal Hakemli, Tıpta Uzmanlık sonrası
Cengiz Ceylan, Fatih Demirkan, Hayri Özsan, Fatih Kuyucuoğlu, Mehmet Ali Özcan, Bülent Ündar, "CD44v6 Expression in non-Hodgkin's Lymphomas", Türk Hematoloji-Onkoloji Dergisi, THOD 12 (1): 14-18, 2002, Araştırma(Research) Makale, Ulusal Hakemli, Tıpta Uzmanlık sonrası
G. Hayri Özsan, Fatih Demirkan, İlhan Öztop, M. Ali Özcan, Filiz Vural, Bülent Ündar, "Spontaneous Remission in Acute Leukemia: A Report of Two Cases", Türk Hematoloji-Onkoloji Dergisi, THOD 12 (2): 99-102, 2002, Olgu Sunumu, Ulusal Hakemli, Tıpta Uzmanlık sonrası
Serra Menekay, G.Hayri Özsan, Fatih Demirkan, Defne Ozbek, Mehmet Ali Ozcan, Meral Fadıloğlu, Bulent Undar, "Effect of granulocyte-colony-stimulating factor on serum lactate dehydrogenase levels and isoenzymes in a rabbit model", Acta Hematologica, Acta Hematol 107:18-22, 2002,

Fatih Demirkan, G. Hayri Özsan, M. Ali Özcan, Filiz Vural, Mine Çabuk, Bülent Ündar, "Plasma Cell Leukemia: A Report of 5 Cases and Review of the Literature", Turkish Journal of Haematology, Turk J Haematol 18 (4): 275-279, 2001, Araştırma(Research) Makale, Ulusal Hakemli, Tıpta Uzmanlık sonrası
G. Hayri Özsan, Özden Pişkin, Fatih Demirkan, Halil Ateş, Mehmet A. Özcan, Bülent Ündar, "Effect of Sialic Acid on Platelet Cryopreservation", Turkish Journal of Haematology, Turk J Haematol 18 (4): 251- 257, 2001, Araştırma(Research) Makale, Ulusal Hakemli, Tıpta Uzmanlık sonrası
Yrd.Doç.Dr. Mesut AKARSU, Doç.Dr. Fatih DEMİRKAN, Doç.Dr. Güner Hayri ÖZSAN, Prof.Dr. Fatoş ÖNEN, Uzm. Faize YÜKSEL, Prof.Dr. Ayşe Şebnem ÖZKAN, Prof.Dr. Bülent ÜNDAR, "Increased levels of tissue factor pathway inhibitor may reflect disease activity and play a role in thrombotic tendency in Behcet's disease.", American Journal of Hematology, Am J Hematol 68(4):225-230, 2001, Araştırma(Research) Makale, SCI-Expanded (10 eserde atıf), Tıpta Uzmanlık sonrası
BALCI P, UNDAR B, YILMAZ E, SECIL M, OZSAN H, CANDA T, "Bilateral breast involvement in Sézary syndrome.", Eur Radiol, 2001; 11: 2468-2471, 2001, Olgu Sunumu, SCI (1 eserde atıf), Tıpta
Uzmanlık sonrası
Demirkan F, Vural F, Özsan G, Özcan M, Özkal S, Ündar B, "Hemophagocytic syndrome associated with inappropiate secretion of antidiuretic hormone in lymphoma and acute myeloblastic leukemia: report of two cases", Leukemia& Lymphoma, Leuk Lymphoma 42(6):1401-1404, 2001, Olgu Sunumu, SCI- Expanded (8 eserde atıf), Tıpta Uzmanlık sonrası
Bülent Ündar, Hayri G. Özsan, Mehmet A. Özcan, Halil Ateş, Fatih Demirkan, Filiz Vural, İlhan Öztop, "B-Kronik Lenfositik Lösemi Hücrelerinin İnvitro CD4+ ve CD8+ T Hücreleri İle Etkileşimi ve İnterferon Alfa'nın Etkisi", Türk Hematoloji-Onkoloji Dergisi, THOD 11 (3), 119-125, 2001, Araştırma(Research) Makale, Ulusal Hakemli, Tıpta Uzmanlık sonrası
BULENT UNDAR, FATIH DEMIRKAN, ILHAN OZTOP, M. ALI OZCAN, G. HAYRI OZSAN, "Concurrent diagnosis of hairy cell leukemia and renal cell carcinoma", Leukemia and Lymphoma, Leuk Lymphoma 42(3):567-568, 2001, Editöre Mektup, SCI-Expanded, Tıpta Uzmanlık sonrası
FATIH DEMIRKAN, ILHAN OZTOP, HAYRI OZSAN, BULENT UNDAR, "Emergence of Philadelphia positive chronic myeloid leukemia in a patient with Philadelphia negative acute lymphoblastic leukemia", Leukemia&Lymphoma, Leuk Lymphoma 42(1-2):251-252, 2001, Editöre Mektup, SCI-Expanded,
Tıpta Uzmanlık sonrası
İlhan Öztop, Fatih Demirkan, G. Hayri Özsan, Halil teş, Mine Çabuk, Bülent Ündar, "Evaluation of Peripheral Blood Platelet Activation and Leukocyte-Platelet Aggregates in Relation to Disease Activity in Inflamatory Bowel Diseases", Türk Hematoloji-Onkoloji Dergisi, THOD 10 (3), 144-150, 2000, Araştırma(Research) Makale, Ulusal Hakemli, Tıpta Uzmanlık sonrası
HAYRI G. OZSAN, MUSTAFA PEHLIVAN, FATIH DEMIRKAN, BULENT UNDAR, MURAT SAYAN, CAVIT CEHRELI, "High lactoferrin levels in disseminated intravascular coagulation and its possible negative role in coagulation", Thrombosis Research, Thromb Res 98(1):111-114, 2000, Araştırma(Research) Makale, SCI, Tıpta Uzmanlık sonrası
A. Yıldız, H. Özsan, O. Dicle, A. Kılıçalp, C. Usal, "Malign-benign lenfadenopati ayrımında renkli doppler US'nin rolü", Tanısal ve girişimsel radyoloji, sayı 6, sayfa 38-42, 2000, 2000, Araştırma(Research) Makale, Ulusal Hakemli, Tıpta Uzmanlık sonrası
Mustafa Pehlivan, Fatih Demirkan, Hayri G. Özsan, Uğur Yılmaz, Bülent Ündar, "Febril Nötropeni Epizotlarında Hematopoietik Büyüme Faktör (G-CSF) Kullanımı", Türk Hematoloji-Onkoloji Dergisi, THOD 10 (1): 9-14, 2000, Araştırma(Research) Makale, Ulusal Hakemli, Tıpta Uzmanlık sonrası
Doç.Dr. Fatih DEMİRKAN, Dr.Mine Çabuk, Doç.Dr. Güner Hayri ÖZSAN, Uzm.Dr.Mustafa Pehlivan, Uzm.Dr. Erdinç YÜKSEL, Doç.Dr. İlhan ÖZTOP, Prof.Dr. Bülent ÜNDAR, "The Use of Different Prognostic Systems Applied to Myelodysplastic Syndromes: A Retrospective Analysis.", Turkish Journal of Haematology, Turk J Haematol 17(3):101-109, 2000, Araştırma(Research) Makale, Ulusal Hakemli, Tıpta Uzmanlık sonrası
Prof.Dr.Cavit Çehreli, Doç.Dr. Güner Hayri ÖZSAN, Doç.Dr. Fatih DEMİRKAN, Halil ATEŞ, Prof.Dr. Bülent ÜNDAR, Uzm. Faize AKYOL YÜKSEL, Doç.Dr. İlhan ÖZTOP, Prof.Dr. Ahmet Uğur YILMAZ, "The Role of Interleukin-1 Inhibitors on Acute Myeloblastic Leukemia Blast Proliferation; Future Potential

for Biotheraphy.", Turkish Journal of Hematology, 16(4):161-166, 1999, Araştırma(Research) Makale, Ulusal Hakemli, Tıpta Uzmanlık sonrası

Çabuk M, Özsan H, Üstün H, Akarsu M, Demirkan F, Kargı A, Ündar B, Çehreli C, "Subklavyan- jugüler-aksiller ven trombozu ile prezente olan, primeri bilinmeyen taşlı yüzük hücreli karsinom vakası", Türk Onkoloji Dergisi, TOD 14 (4): 204-206, 1999, Olgu Sunumu, Ulusal Hakemli, Tıpta Uzmanlık sonrası
Mustafa Pehlivan, Fatih Demirkan, Hayri Özsan, Uğur Yılmaz, Bülent Ündar, "Sitotoksik Tedavi veya Kemik İliği Tutulumuna Bağlı Gelişen 148 Febril Nötropeni Epizodu", Klimik Dergisi, Klimik 12 (3): 93- 96, 1999, Araştırma(Research) Makale, Ulusal Hakemli, Tıpta Uzmanlık sonrası
Fatih DEMİRKAN, Hayri ÖZSAN, Mustafa PEHLİVAN, Bülent ÜNDAR, "Akut Lenfositik Lösemilerde CD34 Ekspresyonu ve Prognostik Önemi", Türk Hematoloji-Onkoloji Dergisi, THOD 9(1): 1-5, 1999, Araştırma(Research) Makale, Ulusal Hakemli, Tıpta Uzmanlık sonrası
Pehlivan M, Yeniçerioğlu Y, Demirkan HMB, Özsan H, Demirkan F, Erdener Erden, Ündar B, "Non- Hodgkin Lenfomada Dilde Aktinomikoz", Flora, 3/3/200-203/1998, 1998, Olgu Sunumu, Ulusal Hakemli, Tıpta Uzmanlık sonrası
Nur Yüceyar, Emre Kumral, Murat Tombuloğlu, Hayri Özsan, "Prethrombotic coagulation abnormalities in young adults with iscemic troke", Turkish Journal of hematology, sayı 15, sayfa83-90, 1998, 1998, Araştırma(Research) Makale, Ulusal Hakemli, Tıpta Uzmanlık sonrası
Mehmet Alakavuklar, Koyuncuoğlu M, Cingöz S, Demirkan HMB, Canda T, Hilmi Alanyalı, Harmancıoğlu Ö, Saydam S, Yılmaz U, Yenici O, Balcı P, Derebek E, Özsan H, Demirkan F, Ündar B, Kınay M, Cavit Çehreli, "Meme Kanserli Hastalarda CD44s, P-glikoproteini ve p53 Metastaz Gelişimini Yansıtabilir mi?", International Journal of Hematology and Oncology, 7/2/73-79/1997, 1997, Araştırma(Research) Makale, Ulusal Hakemli, Tıpta Uzmanlık sonrası
Derebek E, Özsan GH, Berna Değirmenci, Doğan S, Balcı P, Yılmaz M, Demirkan HMB, Hilmi Alanyalı, Mehmet Alakavuklar, Canda T, Durak H, "Tc-99m MIBI Scintigraphy in the Evaluation of Inflamatory Breast Cancer", Turkish Journal of Nuclear Medicine, 6/3/210-214/1997, 1997, Araştırma(Research) Makale, Ulusal Hakemli, Tıpta Uzmanlık sonrası
Demirkan HMB, YILMAZ U, MEHMET ALAKAVUKLAR, ÜNDAR B, DEMİRKAN F, ÖZSAN H, HİLMİ ALANYALI, SAYDAM S, CANDA T, DİCLE O, CAVİT ÇEHRELİ, "Meme Kanseri Tedavisinde Adjuvan Kemoterapi Maliyetinin Araştırılması", Meme Hastalıkları Dergisi, 3/4/158-164/1996, 1996, Araştırma(Research) Makale, ULAKBİM, Tıpta Uzmanlık sonrası
Mehmet Ali Koçdor, İbrahim Özman, Nazif Erkan, Cüneyt Bektaşer, Mehmet Füzün, Hayri Özsan, "Primer kolon lenfomalarında cerrahi", Kolon Rektum Hastalıkları Dergisi, 6/3/199-200/1996, 1996, Araştırma(Research) Makale, Ulusal Hakemli, Tıpta Uzmanlık sonrası
Cengiz Ceylan, Yılmaz U, Özsan H, Demirkan HMB, Hilmi Alanyalı, Uslu T, Yörükoğlu K, Demirkan F, Ündar B, Mehmet Alakavuklar, Cavit Çehreli, "Türkiye'deki Serviks Kanseri Sıklığı Az Gelişmiş Ülkelerle Benzerlik Göstermekte midir?", Acta Ongolocica Turcica, 29/1-2/9-13/1996, 1996, Araştırma(Research) Makale, Ulusal Hakemli, Tıpta Uzmanlık sonrası
Kocaaogullari H, Ozsan GH, Oksel F, Ozturk G, Kandiloglu G, Ustun EE, "Multicentric reticulohistiocytosis", Clinical Rheumatology, sayı 15, sayfa 62-66, yıl 1996, 1996, Olgu Sunumu, SCI (5 eserde atıf), Tıpta Uzmanlık sonrası
Ömer Özütemiz, Hayri Özsan, Sevgi Mir, Tankut İlter, "Primer Bilier sirozda majör histokompatibilite kompleksi (MHC) class I antijenlerinin dağılımı", Gastroenteroloji, cilt 5, sayı 3, yıl 1994, 1994, Araştırma(Research) Makale, Ulusal Hakemli
G. Alper, E. N. Tavmergen, H. Özsan, E. Tavmergen, G. Gümüşdiş, T. Onat, E. Erlacin, "determination of lupus anticoagulant (LA) and antiphospholipid antibodies (APA) in a family with systemic lupus eritematodes (SLE)", zentralblatt für gynakologie, sayı 114, sayfa 509-512, yıl 1992, 1992, Araştırma(Research) Makale, Yurtdışı Hakemli

The Effect of Age on High-Dose Therapy with Autologous Stem Cell Support in Multiple Myeloma: A Single-Center Experience

Yucel, EE (Yucel, Elcin Erdogan) [1] ; Kirmaz, AT (Kirmaz, Ayse Tugce) [2] ; Kakci, M (Kakci, Merve) [3] ; Yavuz, AF (Yavuz, Aylin Fatma) [3] ; Sencelikel, T (Sencelikel, Tugce) [4] ; Alacacioglu, I (Alacacioglu, Inci) [3] ; Ozsan, GH (Ozsan, Guner Hayri) [3]

(provided by Clarivate)

Source

JOURNAL OF CLINICAL MEDICINE

Volume

Issue

DOI

10.3390/jcm13144142

Article Number

4142

Published

JUL 2024

Indexed

2024-08-04

Document Type

Article

Jump to

Abstract

Background: This retrospective one-center study demonstrates the complications related to high-dose therapy with autologous stem cell support (HDT) and the survival of multiple myeloma (MM) patients according to age groups. Methods: We categorized the patients into two groups: those who were <= 65 years old (group 1) (N = 115) and those who were >65 years old (group 2) (N = 26). The mean duration of follow-up was 48 (1-125) months. Results: In group 2 patients, the use of a reduced dosage of melphalan (12 [46%] versus 30 [26%]) was more frequent in comparison to group 1 (p = 0.046). There was a statistically significant difference between the two groups regarding the neutrophil engraftment days (p = 0.001) and the median progression-free survival (PFS) (p = 0.02). The PFS was 44 months for group 1 and 30 months for group 2. There was no statistically significant difference between the groups in relation to the median duration of hospitalization, presence of bacteremia, intravenous antibiotic administration, and overall survival (OS). Conclusions: The study's results indicate that HDT is a reliable method of treatment for older patients with MM, provided that they obtain a suitable conditioning regimen and, furthermore, these patients achieved a comparable OS rate to that of younger patients.

Keywords

Retrospective Evaluation of Clinical, Demographic, and Radiological Data of Orbital Lymphoma Patients: A Single Tertiary Center Experience

Ozizmirliler, D (Ozizmirliler, Denizcan) [1] ; Karakaya, B (Karakaya, Burak) [2] ; Yaman, A (Yaman, Aylin) [3] ; Bajin, MS (Bajin, Meltem Soylev) [1] ; Men, S (Men, Suleyman) [4] ; Demirkan, F (Demirkan, Fatih) [5] ; Ozsan, GH (Ozsan, Guner Hayri) [5] ; Utine, CA (Utine, Canan Asli) [1] , [6]

(provided by Clarivate)

Source

BEYOGLU EYE JOURNAL

Volume

Issue

Page

25-33

DOI

10.14744/bej.2024.84829

Published

2025

Indexed

2025-11-17

Document Type

Article

Jump to

Abstract

Objectives: The objective of the study was to present different clinical presentations, clinical and histopathological features, and treatment outcomes of intraorbital lymphoma. Methods: Medical records of 18 eyes of 17 patients with histopathologically proven diagnoses of intraorbital lymphoma at Dokuz Eyl & uuml;l University Ophthalmology Department, between 2007 and 2022, were reviewed retrospectively. The age, from initial symptoms to diagnosis, follow-up time, and survival times were recorded. Visual acuities at the time of diagnosis and following treatment were evaluated. Results: The mean age of the patients was 63 +/- 19.11 (range: 15-79, median age 65). The most common presenting findings were periorbital swelling, conjunctival mass, and ptosis. Periorbital region involvement was present in 10 of 17 cases (58.8%) and conjunctival involvement was present in 7 cases (41.2%). Biopsy samples were taken from all cases. Non-Hodgkin lymphoma was the most common type of lymphoma, whereas the most common histopathological diagnoses were marginal zone lymphoma and diffuse large B-cell lymphoma. One case was diagnosed with mature T-cell lymphoma. Nine cases had bone marrow involvement. While two cases refused treatment, two cases were not treated due to age and comorbid diseases. Nine cases received chemotherapy, two cases received radiotherapy (RT), 1 case received chemotherapy and RT, and one case received antibiotherapy treatment. In one case with proptosis and exposure keratitis, lateral canthatomy, temporary tarsorrhaphy, and aggressive topical treatment resulted in complete epithelialization of the cornea. Conclusion: Orbital lymphoma is a painless and slowly progressive clinical picture that requires high clinical suspicion because it is a common tumor of the orbit. Although clinical symptoms and findings vary according to the intraorbital location of lymphoma, patients should be examined for systemic involvement and followed up in a multidisciplinary manner.

Keywords

Author Keywords

Intraorbital lymphoma lymphoma orbit orbital lymphoma Intraorbital lymphoma lymphoma

Effects of 27.12 MHz short-waves on fibroblast cell culture and K-562 and ML-1 neoplastic cell lines

Muluk, SY (Muluk, Selkin Yilmaz) [1] ; Özsan, GH (Ozsan, Guner Hayri) [2] ; Öncel, S (Oncel, Sema) [3] ; Ates, H (Ates, Halil) [2]

(provided by Clarivate)

Source

TURKISH JOURNAL OF PHYSICAL MEDICINE AND REHABILITATION

Volume

Issue

Page

83-91

DOI

10.5606/tftrd.2024.14635

Published

2025

Early Access

JUL 2024

Indexed

2024-11-14

Document Type

Article

Jump to

Abstract

Objectives: This study aimed to assess the effect of short-wave therapy (SWT) devices emitting radiofrequency (RF) waves on the proliferation rates of fibroblasts and neoplastic cells. Patients and methods: In this experimental study, fibroblasts cultured from sternal mesenchymal cells of a bypass surgery patient were enriched using stem cell techniques between January 2004 and February 2004. The K-562 and ML-1 neoplastic cell lines were prepared for analysis. Fibroblasts and neoplastic cell lines were exposed to 27.12 MHz short-waves at different energy levels. Continuous short-wave (CSW) was applied at 200 W power, and pulsed short-wave (PSW) was applied at three different mean powers: 1.6 W (PSW-1), 14.9 W (PSW-2), and 54 W (PSW-3). Fibroblast colonies were counted using inverted microscopy, and neoplastic cell proliferation rates were measured using enzyme-linked immunosorbent assay. All short-wave-exposed cells were compared to the controls with no exposure. Results: Short-waves increased the number of fibroblast colonies three- to four-fold across all power levels (1.6 W, 14.9 W, 54 W, and 200 W). They significantly increased K-562 cell proliferation only at 1.6 W and 54 W power levels (p=0.044 and p=0.004, respectively). In contrast, there was no significant increase in ML-1 cell proliferation at any power level tested (p>0.05). Conclusion: This study found that short-waves can boost fibroblast proliferation, potentially aiding tendon healing. However, it also had unpredictable proliferative effects on K-562 cells, as an inconsistent correlation with energy levels was observed. The ML-1 cells were not affected by short-waves, suggesting variability in tumor biology. These findings emphasize the need for precise dosing and personalized treatment strategies when using SWT devices.

Keywords

Author Keywords

Cell proliferation fibroblast cell radiofrequency short-wave therapy

EVALUATION OF CMV DNA ANTIGENEMIA STATUS IN PATIENTS WITH ALLOGENEIC BONE MARROW TRANSPLANT

Keskinkilic, M (Keskinkilic, Merve) [1] ; Solmaz, S (Solmaz, Serife) [2] ; Seyhanli, A (Seyhanli, Ahmet) [3] ; Appak, O (Appak, Ozgur) [4] ; Sayiner, AA (Sayiner, Ayca Arzu) [4] ; Ozsan, GH (Ozsan, Guner Hayri) [5] ; Alacacioglu, I (Alacacioglu, Inci) [5]

(provided by Clarivate)

Source

JOURNAL OF BASIC AND CLINICAL HEALTH SCIENCES

Volume

Issue

Page

236-243

DOI

10.30621/jbachs.1075229

Published

2024

Indexed

2024-07-20

Document Type

Article

Jump to

Abstract

Purpose: The risk of cytomegalovirus (CMV) reactivation following allogeneic hematopoietic stem cell transplantation (ASCT) reaches 30-50%, and there are numerous diagnostic tests to detect CMV replication. The most common tests used in this group of patients include 65kDa phosphoprotein (pp65) antigenemia immunofluorescence assay and nucleic-acid-based quantitative CMV -DNA polymerase chain reaction (qPCR). Material and Methods: In this study, patients who underwent ASCT and developed CMV positivity from 2009 to 2016 in our hospital were evaluated retrospectively. The study included samples of the same patient with antigenemia and CMV -DNA qPCR test for up to 48 hours. The study aimed to determine the factors affecting CMV DNA antigenemia and compare CMV DNA PCR and pp65 antigenemia immunofluorescence assay. Results: The results of 138 specimens of 39 patients who underwent ASCT were evaluated. The mean value of CMV PCR, which was positive for both tests, was 57.887 copies/ml (70- 1.213.633 copies/ml) and a significant correlation was found between the two tests and the positive samples (p = 0.018). The ROC analysis showed that 322 copies/ml CMV viral load in plasma corresponds to >= 1 antigen-positive cells/200 thousand leukocytes (Sensitivity: 68.5%; Specificity: 31.5%). CMV infection was observed in 32 samples; CMV DNA cut-off values of the reference according to CMV DNA PCR and antigenemia results, compared to the development of CMV infection, presented a significant correlation (p=0.004). Conclusion: Although there is a common agreement between antigenemia and CMV DNA PCR tests, one should keep in mind that the sensitivity of antigenemia test is low especially in the neutropenic period.

Keywords

Author Keywords

Allogeneic Hematopoietic Stem Cell Transplantation (ASCT)

The effect of haemoglobin, albumin, lymphocyte and platelet score on the prognosis in patients with multiple myeloma

Solmaz, S (Solmaz, Serife) [1] ; Uzun, O (Uzun, Ozcan) [2] ; Sevindik, OG (Sevindik, Omur Gokmen) [3] ; Demirkan, F (Demirkan, Fatih) [4] ; Ozcan, MA (Ozcan, Mehmet Ali) [4] ; Ozsan, GH (Ozsan, Guner Hayri) [4] ; Alacacioglu, I (Alacacioglu, Inci) [4]

(provided by Clarivate)

Source

INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY

Volume

Issue

Page

13-19

DOI

10.1111/ijlh.13958

Published

FEB 2023

Early Access

SEP 2022

Indexed

2022-09-08

Document Type

Article

Jump to

Abstract

Introduction In multiple myeloma cases, a variety of prognostic parameters have been identified, which contain the Durie-Salmon classification and the international staging system (ISS) that takes the serum ss2 microglobulin and albumin levels, platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR), and monocyte-to-lymphocyte ratio (MLR). This study investigates the effect of haemoglobin, albumin, lymphocyte and platelet (HALP) score which is a marker of inflammation status and nutrition, at the time of diagnosis for the patients with multiple myeloma on prognosis. Methods A total of 200 multiple myeloma patients with HALP scores calculated from serum haemoglobin, albumin, lymphocyte count and platelet levels at the time of diagnosis were retrospectively examined. The effect of HALP score on overall survival (OS) and progression-free survival and its relationship between the previously evaluated prognostic parameters were investigated. Results The optimal cut-off value with the ROC curves for the HALP score was 28.8. The patients were divided into two groups according to the optimal value of the HALP score (low-score group: HALP <= 28.8 [n: 134] and high-score group HALP >28.8 [n: 66]). In the group with the high HALP score, the OS was statistically longer than the low HALP score group (84 months and 53 months; p = 0.0001). In addition, when the effects of NLR, PLR, HALP score and ISS stage on OS were examined by multivariate analysis, all these markers were found to be statistically significant predictors. Conclusions HALP score may be a valuable prognostic marker for patients with multiple myeloma.

Keywords

Author Keywords

HALP score multiple myeloma overall survival prognosis progression-free survival

Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies

Bozdag, SC (Bozdag, Sinem Civriz) [1] ; Seval, GC (Seval, Guldane Cengiz) [1] ; Hindilerden, IY (Hindilerden, Ipek Yonal) [2] ; Hindilerden, F (Hindilerden, Fehmi) [3] ; Andiç, N (Andic, Neslihan) [4] ; Baydar, M (Baydar, Mustafa) [5] ; Kaynar, LA (Kaynar, Lale Aydin) [6] ; Toprak, SK (Toprak, Selami Kocak) [1] ; Göksoy, HS (Goksoy, Hasan Sami) [7] ; Aydin, BB (Aydin, Berrin Balik) [8] ;

(provided by Clarivate)

Source

TURKISH JOURNAL OF HEMATOLOGY

Volume

Issue

Page

43-54

DOI

10.4274/tjh.galenos.2021.2021.0287

Published

2022

Indexed

2022-03-16

Document Type

Article

Abstract

Objective: Patients with solid malignancies are more vulnerable to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection than the healthy population. The outcome of SARS-CoV-2 infection in highly immunosuppressed populations, such as in patients with hematological malignancies, is a point of interest. We aimed to analyze the symptoms, complications, intensive care unit admissions, and mortality rates of patients with hematological malignancies infected with SARS-CoV-2 in Turkey. Materials and Methods: In this multicenter study, we included 340 adult and pediatric patients diagnosed with SARS-CoV-2 from March to November 2020. Diagnosis and status of primary disease, treatment schedules for hematological malignancies, time from last treatment, life expectancy related to the hematological disease, and comorbidities were recorded, together with data regarding symptoms, treatment, and outcome of SARS-CoV-2 infection. Results: Forty four patients were asymptomatic at diagnosis of SARSCoV-2 infection. Among symptomatic patients, fever, cough, and dyspnea were observed in 62.6%, 48.8%, and 41.8%, respectively. Sixtynine (20%) patients had mild SARS-CoV-2 disease, whereas moderate, severe, and critical disease was reported in 101 (29%), 71 (20%), and 55 (16%) patients, respectively. Of the entire cohort, 251 (73.8%) patients were hospitalized for SARS-CoV-2. Mortality related to SARS-CoV-2 infection was 26.5% in the entire cohort; this comprised 4.4% of those patients with mild disease, 12.4% of those with moderate disease, and 83% of those with severe or critical disease. Active hematological disease, lower life expectancy related to primary hematological disease, neutropenia at diagnosis of SARS-CoV-2, ICU admission, and first-line therapy used for coronavirus disease-2019 treatment were found to be related to higher mortality rates. Treatments with hydroxychloroquine alone or in combination with azithromycin were associated with a higher rate of mortality in comparison to favipiravir use. Conclusion: Patients with hematological malignancy infected with SARS-CoV-2 have an increased risk of severe disease and mortality.

Keywords

Author Keywords

COVID-19 SARS-CoV-2 infection Hematological malignancy

Adaptive phenotypic modulations lead to therapy resistance in chronic myeloid leukemia cells

Baykal-Köse, S (Baykal-Kose, Seda) [1] ; Acikgoz, E (Acikgoz, Eda) [2] , [3] ; Yavuz, AS (Yavuz, Ahmet Sinan) [4] ; Geyik, ÖG (Geyik, Oyku Gonul) [1] ; Ate, H (Ate, Halil) [5] ; Sezerman, OU (Sezerman, Osman Ugur) [6] ; Özsan, GH (Ozsan, Guner Hayri) [5] ; Yüce, Z (Yuce, Zeynep) [1]

(provided by Clarivate)

Source

PLOS ONE

Volume

Issue

DOI

10.1371/journal.pone.0229104

Article Number

e0229104

Published

FEB 27 2020

Indexed

2020-06-08

Document Type

Article

Abstract

Tyrosine kinase inhibitor (TKI) resistance is a major problem in chronic myeloid leukemia (CML). We generated a TKI-resistant K562 sub-population, K562-IR, under selective imatinib-mesylate pressure. K562-IR cells are CD34(-)/CD38(-), BCR-Abl-independent, proliferate slowly, highly adherent and form intact tumor spheroids. Loss of CD45 and other hematopoietic markers reveal these cells have diverged from their hematopoietic origin. CD34 negativity, high expression of E-cadherin and CD44; decreased levels of CD45 and beta-catenin do not fully confer with the leukemic stem cell (LSC) phenotype. Expression analyses reveal that K562-IR cells differentially express tissue/ organ development and differentiation genes. Our data suggest that the observed phenotypic shift is an adaptive process rendering cells under TKI stress to become oncogene independent. Cells develop transcriptional instability in search for a gene expression framework suitable for new environmental stresses, resulting in an adaptive phenotypic shift in which some cells partially display LSC-like properties. With leukemic/cancer stem cell targeted therapies underway, the difference between treating an entity and a spectrum of dynamic cellular states will have conclusive effects on the outcome.

Keywords

Keywords Plus

CHRONIC MYELOGENOUS LEUKEMIA ERYTHROID-DIFFERENTIATION E-CADHERIN STEM-CELLS

Clinical Outcomes of CNS Lymphoma Treated with Ibrutinib-Based Therapy: A Real-Life Multicenter Experience on Off-Label Use of Ibrutinib

Iltar, U (Iltar, Utku) [1] ; Salim, O (Salim, Ozan) [1] , [13] ; Atas, U (Atas, Unal) [2] ; Vural, E (Vural, Ece) [1] ; Alhan, FN (Alhan, Fadime Nurcan) [1] ; Yucel, OK (Yucel, Orhan Kemal) [1] ; Sozel, H (Sozel, Hasan) [1] ; Guven, S (Guven, Serkan) [2] ; Geduk, A (Geduk, Ayfer) [4] ; Deveci, B (Deveci, Burak) [5] , [6] ;

(provided by Clarivate)

Source

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI

Volume

Issue

Page

191-197

DOI

10.4999/uhod.237297

Published

2023

Indexed

2024-02-15

Document Type

Article

Abstract

Despite recent therapeutic advances, the prognosis of patients with relapsed/refractory (RR) primary (PCNSL) and secondary central nervous system lymphoma (SCNSL) remains poor. Therefore, the need for new treatment options in CNSL continues. Ibrutinib has been used in clinical trials for CNSL in recent years. However, there is no real -life data on this subject yet. We retrospectively evaluated the efficacy of ibrutinib alone or in combination with various treatment options in 39 patients, 21 with PCNSL and 18 with SCNSL. The median age was 62 years and the overall response rate (ORR) was 59%. The median overall survival (OS) was four months for all patients and 13 months for responder patients (p< 0.001). Invasive aspergillosis occurred in 10.2% of the patients. Lactate dehy- drogenase activity, response to treatment, and the presence of the invasive fungal infection were prognostic factors affecting OS on the ibrutinib therapy (p= 0.04, p= 0.02, and p= 0.048, respectively). There was no significant difference in prognosis between the IBR monotherapy and IBR combination groups. Compared to early -phase clinical studies, lower ORR, shorter OS, and a higher incidence of invasive fungal infections were observed in this real -life study of ibrutinib which was used alone or in a combination regimen in patients with RR PCNSL and SCNSL.

Keywords

Author Keywords

Ibrutinib Central nervous system lymphoma Relapsed/refractory Maintenance Aspergillosis

The Relationship Between Prognosis and Plasma Cell Percentage; Infiltration Pattern, Fibrosis and Microvascular Density in Bone Marrow Biopsies of Plasma Cell Myeloma Patients br

Ozmen, HI (Ozmen, Hazal Izol) [1] ; Seyhanli, A (Seyhanli, Ahmet) ; Ozsan, GH (Ozsan, Guner Hayri) [2] ; Ellidokuz, H (Ellidokuz, Hulya) [3] ; Ozkal, S (Ozkal, Sermin) [4]

(provided by Clarivate)

Source

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI

Volume

Issue

Page

29-36

DOI

10.4999/uhod.236843

Published

2023

Indexed

2023-04-28

Document Type

Article

Abstract

Plasma cell myeloma is a monoclonal disease characterized by anemia, monoclonal protein in serum and or urine, osteolytic in bones, hypercalcemia, and renal failure. The study aims to evaluate the percentage of plasma cells in bone marro , the of bone marro involvement, the intensity of fibrosis and angiogenesis in bone marro , and to assess their relationship ith prognostic markers. In this study, bone marro biopsies of 135 plasma cell myeloma cases ere re-evaluated regarding plasma cell percentage and the pattern of bone marro involvement. Fibrosis as assessed in 132 cases ith reticulin staining and vessel density (M D) in 51 cases ith CD34 staining. The relation of these morphological parameters ith stage and survival lesions pattern clinical as analyzed. Plasma cell percentage, involvement pattern and micro-vessel density sho ed statistically significant micro -status correlation ith stage, hile bone marro fibrosis as not significantly correlated (p 0.05, p 0.001, p 0.011, p 0.05, respectively). percentage of plasma cells, diffuse pattern of bone marro involvement, and increase in the degree of fibrosis as correlated increase in M D (p 0.001, p 0.001, p 0.036 respectively). The present study suggested that evaluation of plasma cell infiltration pattern, fibrosis and micro-vessel density in bone marro biopsies of ne ly diagnosed plasma cell myeloma cases be useful tools in the management and maintenance of the treatment. Elevation in ith an percentage, might

Keywords

Author Keywords

Plasma cell myeloma Bone marro Angiogenesis Fibrosis

Clinical Outcomes and Treatment Patterns of Primary Central Nervous System Lymphoma: Multicenter Retrospective Analysis

Guven, S (Guven, Serkan) [1] , [6] ; Yavuz, B (Yavuz, Boran) [1] ; Yucel, EE (Yucel, Elcin Erdogan) [1] ; Karatas, AF (Karatas, Aylin Fatma) [1] ; Ozsan, GH (Ozsan, Guner Hayri) [1] ; Demirkan, F (Demirkan, Fatih) [1] ; Undar, B (Undar, Bulent) [1] ; Ozcan, MA (Ozcan, Mehmet Ali) [1] ; Kiper, HD (Kiper, Hatice Demet) [2] ; Cetintepe, T (Cetintepe, Tugba) [2] ;

(provided by Clarivate)

Source

EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY

Volume

Issue

Page

49-56

DOI

10.14744/ejmo.2023.64688

Published

2023

Indexed

2024-01-19

Document Type

Article

Jump to

Abstract

Objectives: Primary central nervous system lymphoma (PCNSL) is a rare malignant disease with poor prognosis. Its low incidence leads to challenges in decision-making for treatment. As a matter of fact, there is still no consensus on the appropriate treatment modalities. In this context, the objective of this study is to investigate and comparatively assess the efficacies of several treatment modalities in the treatment of PCNSL.Methods: Thirty-four patients diagnosed with PCNSL at 5 different hematology centers between 2007 and 2021 were included in the study. Patients' data from all five centers were collected retrospectively. Since ibrutinib is not approved for this indication in Turkey, consent for off-label use of ibrutinib is obtained from each patient. Ethics committee approval was obtained on June 9, 2021 with decision number 2021/18-05.Results: The median age of the patients was 59 (min.: 22, max.: 78) years. The male-to-female ratio was 1.26/1. Nineteen (55.9%) patients had Eastern Cooperative Oncology Group (ECOG) performance score of >= 2. Fifteen (44.1%) patients had normal lactate dehydrogenase (LDH) levels and only 14.7% of the patients had B symptoms at the time of diagnosis. Magnetic resonance imaging (MRI) revealed a single mass lesion in 14 (41.2%) patients. As an induction therapy, methotrexate-based regimen was administered in 29 (85.3%) patients. Only 14 of the 34 patients received 4 or more cycles of high-dose methotrexate (MTX). About 32.4% of the patients received radiation therapy (RT) during follow-up as a part of induction therapy. Five patients received only RT due to poor performance status. Ibrutinib was administered in 5 patients for refractory disease. It was determined that four or more cycles of MTX treatment increased progression-free survival (PFS) (p=0.031) and overall survival (OS) (p=0.012). Moreover, RT improved PFS (p=0.023). Considering that the complete response achieved by induction therapy influences long-term survival, achievement of the best response to the treatment regimens administered in combination with new agents may prolong survival (PFS: p=0.01, OS: p=0.023).Conclusion: The findings of this study indicate that the initial response to treatment is crucial. Additionally, it was found that high-dose MTX treatment should be administered for 4 cycles or more in order to achieve the best results. Furthermore, it was determined that ibrutinib monotherapy was well-tolerated in our patients with relapsed/refractory disease, with excellent clinical benefits. In conclusion, a combination therapy consisting of high-dose MTX, ibrutinib, and rituximab appears to be a promising initial treatment approach in appropriate patients.

Keywords

Author Keywords

PCNSL methotrexate radiotherapy ibrutinib

Can Neutrophil-to-Lymphocyte Ratio, Monocyte-to-Lymphocyte Ratio, and Platelet-to-Lymphocyte Ratio at Day+100 be used as a prognostic marker in Multiple Myeloma patients with autologous transplantation?

Medeni, SS (Medeni, Serife Solmaz) [1] ; Acar, C (Acar, Celal) [1] ; Olgun, A (Olgun, Aybuke) [2] ; Acar, A (Acar, Alev) [2] ; Seyhanli, A (Seyhanli, Ahmet) [2] ; Taskiran, E (Taskiran, Emin) [2] ; Sevindik, OG (Sevindik, Omur Gokmen) [3] ; Alacacioglu, I (Alacacioglu, Inci) [2] ; Piskin, O (Piskin, Ozden) [2] ; Ozcan, MA (Ozcan, Mehmet Ali) [2] ;

(provided by Clarivate)

Source

CLINICAL TRANSPLANTATION

Volume

Issue

DOI

10.1111/ctr.13359

Article Number

e13359

Published

SEP 2018

Indexed

2018-10-03

Document Type

Article

Abstract

Background: Recent reports have showed that neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR) are predictors of progression-free survival (PFS) and overall survival (OS) in many types of cancer. This study evaluates the predictive value of NLR, MLR, and PLR for survival in MM patients treated with to ASCT.

Methods: A set of data consisting of 150 patients who underwent autologous stem cell transplantation (ASCT) for MM was collected retrospectively. The prognostic value of NLR, MLR, and PLR was investigated with Kaplan-Meier method.

Results: The prognostic value of NLR, MLR, and PLR was analyzed by a receiver operating characteristic (ROC) curve established to determine the cutoff. These cutoff values of NLR, PLR, and MLR were found 1.46, 86, and 0.27, respectively, on the 100th day of post-transplantation period. The overall survival (OS) and the post-transplantation OS of the patients with high NLR, MLR, and PLR levels on the 100th day of post-transplantation were shorter than the other group (P = 0.05, P = 0.018 [NLR], P = 0.05, P = 0.002 [MLR], P = 0.000, P = 0.001 [PLR]). The post-transplantation progression-free survival (PFS) of the patients with high NLR, MLR, and PLR levels on the 100th day of post-transplantation was shorter as well (P = 0.036, P = 0.001, P = 0.001, respectively).

Conclusion: As increased NLR, MLR, and PLR predicted poor clinical outcome in MM patients with autologous transplantation in this study, they may serve as cost-effective and rapidly available prognostic biomarkers for these patients.

Keywords

Author Keywords

Monocyte Lymphocyte Ratio (MLR)Multiple myeloma Neutrophil-to-Lymphocyte Ratio (NLR)

Therapeutic plasma exchange in neurological diseases: Eleven years experience at a tertiary care center in Turkey

Seyhanli, A (Seyhanli, Ahmet) [1] ; Yavuz, B (Yavuz, Boran) [2] ; Selimoglu, I (Selimoglu, Ismail) [3] ; Sengun, IS (Sengun, Ihsan Sukru) [4] ; Aslan, AT (Aslan, Abdullah Taha) [4] ; Ozsan, GH (Ozsan, Guner Hayri) [2] ; Alacacioglu, I (Alacacioglu, Inci) [2] ; Demirkan, F (Demirkan, Fatih) [2]

(provided by Clarivate)

Source

THERAPEUTIC APHERESIS AND DIALYSIS

Volume

Issue

Page

465-470

DOI

10.1111/1744-9987.13703

Published

APR 2022

Early Access

JUN 2021

Indexed

2021-07-09

Document Type

Article

Jump to

Abstract

Therapeutic plasma exchange (TPE) is an apheresis procedure in which plasma is separated from the blood cellular components ex vivo, allocated, and replaced with another plasma or a plasma-replacing fluid. This study aimed to define the rate of complications and determine TPE distribution in various neurological diseases. Our study is a retrospective analysis of neurologic diseases requiring TPE between 2008 and 2019 that were selected using the medical records of neurology departments and apheresis units database. We performed 1459 TPE procedures on 207 patients between 2008 and 2019. TPE Procedure is most frequently applied in patients with Myasthenia-Gravis syndrome (34.7%). The complication ratio was 1.6% from a total of 1459 TPE procedures. The most commonly specified adverse event was allergic reactions 11 (5.3%), followed by hypotension 6 (2.9%). TPE was safe and tolerable, with manageable complications in experienced hands.

Keywords

Author Keywords

acute inflammatory demyelinating polyradiculoneuropathy (AIDP)chronic inflammatory

Evaluation of disease spectrum diagnosed with bone marrow biopsy at a tertiary healthcare center in Turkey Hematological diseases spectrum diagnosed with bone marrow biopsy

Seyhanli, A (Seyhanli, Ahmet) [1] ; Ozkan, YC (Ozkan, Yazgulu Cansu) [2] ; Ozkal, S (Ozkal, Sermin) [3] ; Ozsan, GH (Ozsan, Guner Hayri) [4] ; Demirkan, F (Demirkan, Fatih) [4] ; Alacacioglu, I (Alacacioglu, Inci) [4]

(provided by Clarivate)

Source

ANNALS OF CLINICAL AND ANALYTICAL MEDICINE

Volume

Issue

Page

788-791

DOI

10.4328/ACAM.21122

Published

JUL 2022

Indexed

2022-07-27

Document Type

Article

Jump to

Abstract

Aim: Bone marrow examination (BME) is commonly implemented to diagnose hemato-oncological diseases. There are only a few reports on diseases diagnosed via the BME and diagnostic yield in patients who applied to the hematology department This study aimed to identify the primary indications and diagnoses of BME in patients who underwent bone marrow biopsy at Dokuz Eylul University in Turkey.

Material and Methods: We retrospectively reviewed demographic and laboratory data of 505 patients from January 2014 to September 2021. The cases under the age of 18 years were excluded. The patients were also stratified according to demographic data and diagnoses.

Results: Among the 505 bone marrow biopsies (BMB) studied, 386 (76.4%) procedures were performed to evaluate suspected malignancy and 119 (23.6%) for non-malignant indications. The primary indications for BME were: cytopenia (117,23.2%), plasma cell neoplasm (PCN) (94, 18.6%), and myeloproliferative neoplasms (93, 18.4%). The most common diagnoses among all patients were PCN (110, 21.8%). Non-malignant outcomes comprised 3.2% of the total outcomes with 16 cases, of which thrombocytopenia due to peripheral destruction (immune thrombocytopenia) was the most common with eight (1.6%) patients. The majority of patients diagnosed with myelodysplastic syndrome and CLL were seen in patients aged 65 years and older.

Discussion: There is little published literature on the bone marrow profile, especially in geriatric patients. The higher incidence of hematological diseases in patients under 65 years of age can be attributed to more common BME procedures, which leads to earlier diagnosis.

Keywords

Author Keywords

Hematologic Diseases Trephine Biopsy Bone Marrow

Computed tomography characteristics of multiple myeloma and other osteolytic metastatic bone lesions

Mutlu, U (Mutlu, Uygar) [1] ; Balci, A (Balci, Ali) [1] ; Özsan, GH (Ozsan, Guner Hayri) [2] ; Özkal, S (Ozkal, Sermin) [3] ; Seyhanli, A (Seyhanli, Ahmet) [2] ; Özgül, HA (Ozgul, Hakan Abdullah) [1]

(provided by Clarivate)

Source

ACTA RADIOLOGICA

Volume

Issue

Page

1639-1647

DOI

10.1177/0284185120977035

Article Number

0284185120977035

Published

DEC 2021

Early Access

DEC 2020

Indexed

2021-08-13

Document Type

Article

Jump to

Abstract

Background Differentiation of multiple myeloma (MM) from osteolytic metastatic (OM) bone lesions may be critical in patients with lytic bone lesions but can be challenging for radiologists. Purpose To determine whether computed tomography (CT) can be used to distinguish between MM and other OM bone lesions. Material and Methods In this retrospective study, 320 lesions of 207 patients diagnosed with MM or OM, based on biopsy or clinical examination, were evaluated. Eight qualitative features were evaluated by two radiologists blinded to the diagnoses. The chi-square and Fisher exact tests, and logistic regression analysis, were used to evaluate the relationships between the CT findings and diagnoses. Results High-density areas were more common in OM than MM lesions (85.2% and 19%, P < 0.001), as were perilesional sclerosis (38.9% vs. 13.2%, P < 0.001), heterogeneity (on non-contrast CT images, 60% vs. 19.1%, P < 0.001; on contrast enhanced CT images, 80.6% vs. 28.2%, P < 0.001), and ill-defined margins (34.6% vs. 9.1%, P < 0.001). Similarly, OM lesions showed high-density areas more than MM in evaluation of skeletal system subgroups (vertebrae, 93.8% vs. 29.8%, P < 0.0001; thoracic cage bones, 69.6% vs. 19.2%, P < 0.001; pelvic bones and sacrum, 84.8% vs. 7.7%, P < 0.001; peripheral skeletal bones, 81.5% vs. 8.3%, P < 0.001). Logistic regression analysis revealed that the presence of a high-density area in the lesion increased the probability of a metastasis 25.88-fold (R-2 = 0.516, P < 0.001). Conclusion MM and OM lesions can be differentiated by CT; OM lesions exhibit high- density areas.

Keywords

Author Keywords

Multiple myeloma osteolytic metastatic bone lesions computed tomography computed

Evaluation of using fresh frozen plasma for patients with cirrhosis at a tertiary healthcare center in Turkey: Strict transfusion policies are essential

Seyhanli, A (Seyhanli, Ahmet) [1] ; Ozkan, YC (Ozkan, Yazgulu Cansu) [2] ; Bengi, G (Bengi, Goksel) [3] ; Alacacioglu, I (Alacacioglu, Inci) [4] ; Ozsan, GH (Ozsan, Guner Hayri) [4] ; Demirkan, F (Demirkan, Fatih) [4]

(provided by Clarivate)

Source

TRANSFUSION AND APHERESIS SCIENCE

Volume

Issue

DOI

10.1016/j.transci.2021.103247

Article Number

103247

Published

DEC 2021

Early Access

DEC 2021

Indexed

2022-01-01

Document Type

Article

Abstract

Aim: Management of blood transfusions is a critical issue, especially in cirrhotic patients, because of the absence of national policies in many countries. Fresh frozen plasma (FFP) is a common blood component misused excessively in various clinical situations and cirrhosis patients without any scientific rationale. We evaluated the FFP transfusions in patients with cirrhosis at our tertiary care hospital.

Material and Method: The cases with cirrhosis diagnosed between 2014 and 2020 were selected using the hospital database. The appropriateness of FFP transfusion was determined based on the Practice Guidance by the American Association for the Study of Liver Diseases and Italian guidelines.

Result: Two hundred and six liver cirrhosis patients were identified who received FFP transfusion. The median age was 63 (22-94). Of the 206 patients, 79 (38.3 %) were female, and 127 (61.7 %) were men. The most common causes of liver cirrhosis were alcohol (27.7 %). 45.6 % of the patients were in Child-Pugh Class C. We found 62.1 % of FFP replacements were inappropriately used. Most inappropriate use of FFP (22.8 %, n = 47) occurred to correct prolonged INR in the absence of bleeding.

Conclusion: To avoid inappropriate usage of FFP, regular utilization reviews and formal education programs can be helpful. Our clinic has planned to arrange educational programs for physicians to use blood products appropriately and minimize transfusion-related side effects.

Keywords

Author Keywords

Fresh frozen plasma transfusion Patient blood management Liver cirrhosis

Prognostic Factors in Elderly Patients with Diffuse Large B-Cell Lymphoma and Their Treatment Results

Adiyaman, SC (Adiyaman, Suleyman Cem) [1] ; Alacacioglu, I (Alacacioglu, Inci) [2] ; Danyeli, AE (Danyeli, Ayca Ersen) [3] ; Türkyilmaz, D (Turkyilmaz, Dogus) [2] ; Sevindik, ÖG (Sevindik, Omur Gokmen) [2] ; Demirkan, F (Demirkan, Fatih) [2] ; Piskin, Ö (Piskin, Ozden) [2] ; Özcan, MA (Ozcan, Mehmet Ali) [2] ; Ündar, B (Undar, Bulent) [2] ; Özkal, S (Ozkal, Sermin) [3] ;

(provided by Clarivate)

Source

TURKISH JOURNAL OF HEMATOLOGY

Volume

Issue

Page

81-87

DOI

10.4274/tjh.galenos.2019.2018.0219

Published

2019

Indexed

2019-05-17

Document Type

Article

Abstract

Objective: Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL). The treatment of older NHL patients has always been a struggle; however, treatment statistics have begun showing favorable results similar to those of younger DLBCL patients thanks to newer treatment protocols. Here, we analyze the progress of our own elderly DLBCL patients who were followed between 2000 and 2016 in our center.

Materials and Methods: Eighty-seven DLBCL patients, who were diagnosed and treated in the Dokuz Eylul University Department of Hematology between 2000 and 2016, were included in this study. Median age was 72 (65-89) years and 13 (14.9%) patients were older than 80 years.

Results: Median follow-up time was 19 months and 45 patients (51.7%) died during the follow-up period. Median overall survival (OS) was 55 months and median progression-free survival was calculated as 27 months. Sixty-three patients (72.4%) received standard R-CHOP therapy. Complete response was seen in 46 (52.9%) patients. The median survival time for patients who had complete response was 136 months (p< 0.001); however, OS was not statistically different between older (> 80 years) and younger patients (p=0.236).

Conclusion: According to our findings, we think that being able to complete standard R-CHOP therapy is vital for the survival rate of elderly DLBCL patients.

Keywords

Lymphoid cell neoplasms B-Cell neoplasms Lymphomas Non-Hodgkin lymphoma

Renal and Neurological Response with Eculizumab in a Patient with Transplant Associated Thrombotic Microangiopathy after Allogeneic Hematopoietic Progenitor Cell Transplantation

Sevindik, ÖG (Sevindik, Omur Gokmen) [1] ; Alacacioglu, I (Alacacioglu, Inci) [1] ; Katgi, A (Katgi, Abdullah) [1] ; Solmaz, SM (Solmaz, Serife Medeni) [1] ; Acar, C (Acar, Celal) [1] ; Piskin, Ö (Piskin, Ozden) [1] ; Özcan, MA (Ozcan, Mehmet Ali) [1] ; Demirkan, F (Demirkan, Fatih) [1] ; Ündar, B (Undar, Bulent) [1] ; Özsan, GH (Ozsan, Guner Hayri) [1]

(provided by Clarivate)

Source

CASE REPORTS IN HEMATOLOGY

Volume

2015

DOI

10.1155/2015/425410

Article Number

425410

Published

2015

Indexed

2015-01-01

Document Type

Article

Abstract

Transplantation-associated thrombotic microangiopathy (TA-TMA) is a challenge after allogeneic hematopoietic progenitor cell transplantation, considering the diagnostic uncertainties and lack of established treatment. We report a 43-year-old male patient who was diagnosed as TA-TMA after allogeneic progenitor cell transplantation for a progressive ALK negative anaplastic large cell lymphoma and responded to eculizumab with dramatically improving neurological status and renal function. Rapid neurological and renal recovery achieved after eculizumab could support a possible relationship between complement activation and TA-TMA. Eculizumab should be a reasonable treatment approach in patients with TA-TMA after allogeneic hematopoietic progenitor cell transplantation.

Keywords

Keywords Plus

CRITERIA CHILDREN

What are the factors affecting survival after autologous stem cell transplantation in patients with multiple myeloma?

Solmaz, S (Solmaz, Serife) [1] ; Acar, C (Acar, Celal) [2] ; Seyhanli, A (Seyhanli, Ahmet) [2] ; Sevindik, OG (Sevindik, Omur Gokmen) [3] ; Piskin, O (Piskin, Ozden) [2] ; Ozcan, MA (Ozcan, Mehmet Ali) [2] ; Demirkan, F (Demirkan, Fatih) [2] ; Undar, B (Undar, Buelent) [2] ; Alacacioglu, I (Alacacioglu, Inci) [2] ; Ozsan, GH (Ozsan, Guner Hayri) [2]

(provided by Clarivate)

Source

INDIAN JOURNAL OF TRANSPLANTATION

Volume

Issue

Page

57-62

DOI

10.4103/ijot.ijot_15_19

Published

JAN-MAR 2020

Indexed

2021-04-25

Document Type

Article

Abstract

Introduction: High-dose chemotherapy (HDC) and autologous stem cell transplantation(ASCT) still remains in the treatment of myeloma patients even during the period of new agents. Materials and Methods: We analysed the prognostic affect of pretransplant characteristics and transplant modalities on response, in 150 autologous transplant of 144 multiple myeloma (MM) patients who were transplanted in our centre between 2008 to 2017. We evaluated the affect of age, type of MM, previous treatment regimens, status pre and postfrom transplantation, time of ASCT, neutrophil and platelet engraftmant days, dose of reinfused CD34+ cells, plasma cell infiltration, international staging system(ISS) and Durie -Salmon stage at diagnosis. We examined the affect of these status on overall survival(OS) and eventfree survival(EFS). Results: The median OS and EFS after transplanation were 41 and 28 months, respectively. Median OS after the diagnosis was 57 months. Transplant-related mortality was 3,3%. We found that the lower beta 2- microglobulin levels,lower ISS stage,lower plasma cell infiltration, achievement good responds at the +100th day of post transplant were statistically significant independent predictor factors for longer EFS and OS. When the patients were given chemotherapy regimen with bortezomib before transplantation, these patients were seen to be a better response rate. There was showed a relationship between the using of bortezomib before transplantation with EFS(P = 0.017), but there was no relationship with OS. Conclusions: Our analysis confirms HDCT-ASCT as an effective and safe therapeutic strategy in multiple myeloma patients. This results were independent of age, first line treatment regimens and renal insufficiency. Patients with a high ISS stage were found to have shorter survival(P = 0.002). However, the EFS and OS were longer of the patients whose have good response at the 100th day of transplantation(P = 0,002, P = 0,02).

Keywords

Author Keywords

Autologous stem cell transplantation event-free survival multiple myeloma overall survival

Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy

Walewski, J (Walewski, Jan) [1] ; Hellmann, A (Hellmann, Andrzej) [2] ; Siritanaratkul, N (Siritanaratkul, Noppadol) [3] ; Ozsan, GH (Ozsan, Guner Hayri) [4] ; Ozcan, M (Ozcan, Muhit) [5] ; Chuncharunee, S (Chuncharunee, Suporn) [6] ; Goh, AS (Goh, Ai Sim) [7] ; Jurczak, W (Jurczak, Wojciech) [8] ; Koren, J (Koren, Jan) [9] ; Paszkiewicz-Kozik, E (Paszkiewicz-Kozik, Ewa) [1] ;

(provided by Clarivate)

Source

BRITISH JOURNAL OF HAEMATOLOGY

Volume

183

Issue

Page

400-410

DOI

10.1111/bjh.15539

Published

NOV 2018

Indexed

2018-12-28

Document Type

Article

Abstract

Some patients with relapsed/refractory Hodgkin lymphoma (HL) are not considered suitable for stem cell transplant (SCT) and have a poor prognosis. This phase IV study (NCT01990534) evaluated brentuximab vedotin (1 center dot 8 mg/kg intravenously once every 3 weeks) in 60 patients (aged >= 18 years) with CD30-positive relapsed/refractory HL, a history of >= 1 prior systemic chemotherapy regimen, who were considered unsuitable for SCT/multi-agent chemotherapy. Primary endpoint was overall response rate (ORR) per independent review facility (IRF). Secondary endpoints included duration of response (DOR), progression-free survival (PFS) per IRF, overall survival (OS), proportion proceeding to SCT and safety. The ORR was 50%, with 12% CR; 47% proceeded to SCT. Median DOR was 4 center dot 6 months and median duration of CR was 6 center dot 1 months. After a median follow-up of 6 center dot 9 and 16 center dot 6 months, median PFS and OS were 4 center dot 8 months (95% confidence interval, 3 center dot 0-5 center dot 3) and not reached, respectively; estimated OS rate was 86% at 12 months. Most common adverse events (>= 10%) were peripheral neuropathy (35%), pyrexia (18%), diarrhoea and neutropenia (each 10%). Brentuximab vedotin showed notable activity with a safety profile consistent with known toxicities, and may act as a bridge to SCT, enabling high-risk patients who achieve suboptimal response to frontline/salvage chemotherapy/radiotherapy to receive potentially curative SCT.

Keywords

Author Keywords

Hodgkin lymphoma relapsed/refractory novel anti-tumour agents brentuximab vedotin phase IV

Does Reinfusion of Stem Cell Products on Multiple Days Affect Engraftment?

Medeni, SS (Medeni, Serife Solmaz) [1] ; Türkyilmaz, D (Turkyilmaz, Dogus) [2] ; Acar, C (Acar, Celal) [1] ; Sevindik, ÖG (Sevindik, Omur Gokmen) [3] ; Yüksel, F (Yuksel, Faize) [2] ; Piskin, Ö (Piskin, Ozden) [2] ; Özcan, MA (Ozcan, Mehmet Ali) [2] ; Demirkan, F (Demirkan, Fatih) [2] ; Ündar, B (Undar, Bulent) [2] ; Alacacioglu, I (Alacacioglu, Inci) [2] ;

(provided by Clarivate)

Source

TURKISH JOURNAL OF HEMATOLOGY

Volume

Issue

Page

271-276

DOI

10.4274/tjh.2018.0071

Published

DEC 2018

Indexed

2019-02-13

Document Type

Article

Abstract

Objective: High-doses of melphalan treatment with autologous stem cell transplantation in multiple myeloma (MM) remains a major treatment modality in suitable patients. A minimal dose of 2x10(6)/kg CD34+ cells is preferred to achieve engraftment. Some patients need multiple leukapheresis procedures to achieve the necessary number of CD34+ cells, but this can cause a high volume of stem cell product that cannot be given in a single day. Whether or not the number of infusion days affects engraftment has not been studied before. We aimed to evaluate the impact of reinfusion of stem cells on multiple days on engraftment results.

Materials and Methods: Demographic features, CD34+ cell doses, neutrophil and platelet engraftment days, hospitalization days, and number of infusion days of 149 autologous transplantations of 143 MM patients were evaluated retrospectively.

Results: The data of 143 MM patients who were transplanted were analyzed retrospectively. Median age was 55 +/- 8.5 (range: 26-70) years with a male/female ratio of 91/58. Hospitalization days for all patients were 24 +/- 6 (range: 14-50) days. Mean CD34+ cell number was (7.5 +/- 5.3) x10(6)/kg (range: 1.5-31x10(6)/kg). CD34+ cells were reinfused in 1 day in 80.5% (n=120) of the patients, 2 days in 18.2% of the patients (n=27), and 3 days in 1.3% of the patients (n=2). For 29 patients, reinfusion was applied in more than 1 day because of the high volume of stem cell product. We did not see any dimethyl sulfoxide toxicity, cardiac arrhythmia, or volume overload complications. Hypertensive attacks during infusion were easily controlled by furosemide treatment. In the group with multiple infusions, the infused CD34+ cell numbers had a mean of (4.8 +/- 2.8)x10(6)/kg, and in the single infusion group the mean was (8.1+5.5)x10(6)/kg. There were no statistical differences between the two groups regarding platelet and neutrophil engraftment days (p=0.850, r=0.820 and p=0.500, r=0.440). There was no statistical difference between the two groups for hospitalization days (p=0.060, r=0.050).

Conclusion: In cases with a high volume of stem cell product to acquire adequate stem cells, reinfusion can be safely applied across multiple days without any delay in engraftment.

Keywords

Author Keywords

Multiple myeloma Autologous transplantation Multiple reinfusion days

Hypoalbuminemia is a surrogate biomarker of poor prognosis in myelodysplastic syndrome even when adjusting for comorbidities

Sevindik, OG (Sevindik, Omur Gokmen) [1] ; Guc, Z (Guc, Zeynep) [2] ; Kahraman, S (Kahraman, Selda) [3] ; Solmaz, SM (Solmaz, Serife Medeni) [1] ; Katgi, A (Katgi, Abdullah) [1] ; Acar, C (Acar, Celal) [1] ; Alacacioglu, I (Alacacioglu, Inci) [1] ; Piskin, O (Piskin, Ozden) [1] ; Ozsan, GH (Ozsan, Guner Hayri) [1] ; Demirkan, F (Demirkan, Fatih) [1] ;

(provided by Clarivate)

Source

LEUKEMIA & LYMPHOMA

Volume

Issue

Page

2552-2555

DOI

10.3109/10428194.2015.1014362

Published

2015

Indexed

2016-03-02

Document Type

Article

Abstract

The serum albumin (SA) level has been reported to be an independent prognostic biomarker that may serve as a surrogate representative of disease biology in patients diagnosed with myelodysplastic syndrome (MDS). However, its prognostic ability has not been tested in a model adjusting for comorbidities. We analyzed 200 patients who were diagnosed as having de novo MDS. Median overall survival (OS) of all patients was 25 months and median leukemia-free survival (LFS) was 24 months. Median OS according to the SA level groups of <= 3.5, 3.6-4.0 and > 4.0 mg/dL were 24, 39 and 77 months, respectively. SA level remained an independent predictor of both LFS and OS even when adjusting for the hematopoietic cell transplant comorbidity index (HCT-CI) and the International Prognostic Scoring System (IPSS) or World Health Organization classification-based Prognostic Scoring System (WPSS). Our findings indicate that SA level at the time of diagnosis is a significant and independent predictor of LFS and OS even when adjusting for commonly used prognostic systems and comorbidities.

Keywords

Author Keywords

Myelodysplastic syndrome albumin HCT-CI leukemia-free survival overall survival

Hematopoietic recovery kinetics predicts for poor CD34+ cell mobilization after cyclophosphamide chemotherapy in multiple myeloma

Ozsan, GH (Ozsan, Guner Hayri) [2] ; Micallef, IN (Micallef, Ivana N.) [1] ; Dispenzieri, A (Dispenzieri, Angela) [1] ; Kumar, S (Kumar, Shaji) [1] ; Lacy, MQ (Lacy, Martha Q.) [1] ; Dingli, D (Dingli, David) [1] ; Hayman, SR (Hayman, Suzanne R.) [1] ; Buadi, FK (Buadi, Francis K.) [1] ; Wolf, RC (Wolf, Robert C.) [1] ; Gastineau, DA (Gastineau, Dennis A.) [1] ;

(provided by Clarivate)

Source

AMERICAN JOURNAL OF HEMATOLOGY

Volume

Issue

Page

1-4

DOI

10.1002/ajh.22179

Published

JAN 2012

Indexed

2012-03-10

Document Type

Article

Abstract

Autologous stem cell transplantation is an important part of therapy in patients with multiple myeloma. Some patients fail to collect the desired number of stem cells while others require multiple apheresis to reach the desired apheresis target. The aim of this study was to determine the predictive factors and if the hematopoietic kinetics of recovery were predictive for outcome of stem cell mobilization in cyclophosphamide + growth factor (CY-GF) mobilized patients. Three hundred and ninety six consecutive CY-GF mobilization attempts between January 2000 and December 2009 at Mayo Clinic, Rochester, MN were analyzed. Patients were divided into three groups: optimal (>5 x 106 CD34/kg), suboptimal (25 x 106 CD34/kg) and poor (<2 x 106/kg CD34+ cells) mobilization groups. About 86% of patients had optimal stem cell collection, whereas 8% had suboptimal collection and 6% had poor (or failed) collections. Age, Hb, WBC, and platelet levels had an impact on mobilization results. Time to peripheral blood (PB) CD34+cells >10/mu L predicted for efficiency of collection and the interval between recovery of WBC>1 post-CY to PB CD34+ cells>10 was shorter in the optimal collection groups. These findings suggest that for patients with a PB CD34+ cell count below 10/mu L on Day 13 following CY or 1 day after the WBC>1 x 109/L, addition of plerixafor may be helpful to salvage the mobilization attempt. Am. J. Hematol., 2012. (C) 2011 Wiley Periodicals, Inc.

Keywords

Keywords Plus

BLOOD PROGENITOR-CELL COLONY-STIMULATING FACTOR PERIPHERAL-BLOOD STEM-CELLS

Effects of bone marrow fibrosis and angiogenetic structure on autologous hematopoietic stem cell engraftment

Büyükkurt, N (Buyukkurt, Nurhilal) [1] ; Özsan, GH (Ozsan, Guner Hayri) [2] ; Özkal, S (Ozkal, Sermin) [3] ; Seydaoglu, G (Seydaoglu, Gulsah) [4] ; Alacacioglu, I (Alacacioglu, Inci) [2] ; Özcan, MA (Ozcan, Mehmet Ali) [2] ; Demirkan, F (Demirkan, Fatih) [2] ; Piskin, Ö (Piskin, Ozden) [2] ; Ündar, B (Undar, Bulent) [2]

(provided by Clarivate)

Source

CUKUROVA MEDICAL JOURNAL

Volume

Issue

Page

499-506

DOI

10.17826/cutf.296629

Published

2017

Indexed

2017-11-23

Document Type

Article

Abstract

Purpose: Hematopoietic stem cell (HSC) engraftment is influenced by many factors. We investigated the effects of bone marrow fibrosis and angiogenetic structure on engraftment in patients with hematological malignancies.

Materials and Methods: Data were collected from 34 patients (20 males and 14 females) who underwent autologous HSC transplantation. Bone marrow myelofibrosis was graded from 0 to 3, angiogenesis was quantified using a stereological method in the most recent bone marrow biopsy before the transplantation. Patients were categorized into two groups according to intensity of angiogenesis parameters.

Results: Half of the patients had fibrosis and majority had multiple myeloma (73.5%). Eleven patients had grade 1, six had grade 2 myelofibrosis. The engraftment day (ED) for platelets and erythrocytes was significantly different between the grade 2 fibrosis and non-fibrosis groups. VSD and NVES levels were significantly higher in the grades 1 and 2 fibrosis groups than the no fibrosis group. While the overall survival time was shorter in the grade 2 fibrosis group than the others, the difference was not statistically significant.

Conclusion: Bone marrow fibrosis was found to be independent risk factor. It may have a negative effect on platelet and erythrocyte engraftment time of autologous transplantation process but this effect does not influence survival.

Keywords

Author Keywords

Bone marrow fibrosis angiogenesis autologous transplantation multiple myeloma

Study for the diagnostic screening of paroxsymal nocturnal hemoglobinuria in Turkey: Prospective multicentric evaluation of suspected patients

Ilhan, O (Ilhan, Osman) [1] ; Ozdemir, ZN (Ozdemir, Zehra Narli) [1] ; Ozet, G (Ozet, Gulsum) [1] ; Falay, M (Falay, Mesude) [1] ; Yenerel, M (Yenerel, Mustafa) [1] ; Tuglular, T (Tuglular, Tulin) [1] ; Turgut, M (Turgut, Mehmet) [1] ; Guvenc, B (Guvenc, Birol) [1] ; Unal, A (Unal, Ali) [1] ; Ayyildiz, O (Ayyildiz, Orhan) [1] ;

(provided by Clarivate)

Source

TRANSFUSION AND APHERESIS SCIENCE

Volume

Issue

Page

659-662

DOI

10.1016/j.transci.2019.08.021

Published

OCT 2019

Indexed

2020-01-09

Document Type

Article

Abstract

Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disease presenting with variable and various clinical findings. PNH might be overlooked and diagnosis may be delayed due to low awareness about PNH. This is the first multicenter study in Turkey, investigating the efficiency of diagnostic screening of PNH by multiparameter flow cytometry (FCM) according to consensus guidelines.

Methods: We evaluate the efficiency of consensus clinical indications for PNH testing with FCM in 1689peripheral blood samples from 20 centers between January 2014 and December 2017.

Results: Overall, at the 20 centers contributing to this study, PNH clone were detected in 62/1689 samples (3.6%) by FCM test. 75.8% (n = 47) of patients with PNH clone had aplastic anemia, 3.2% (n = 2) had Coombs (-) hemolytic anemia, 6.5% (n = 4) had unexplained cytopenia, 3.2% (n = 2) had MDS with refractory anemia, 1.6% (n = 1) had hemoglobinuria and 9.7% (n = 6) had others (elevated LDH, splenomegaly, etc.). In contrast, we detect no PNH clone test in patients who were screened for unexplained thrombosis.

Conclusions: Our study showed that current clinical indications for PNH testing are highly efficient and diagnostic screening of suspected patients for PNH with FCM is recommended. However, advanced screening algorithms are required for patients presenting with unexplained thrombosis and normal complete blood count.

Keywords

Author Keywords

Paroxysmal nocturnal hemoglobinuria Multiparameter flow cytometry Diagnostic screening

Nilotinib Does Not Alter the Secretory Functions of Carotid Artery Endothelial Cells in a Prothrombotic or Antithrombotic Fashion

Katgi, A (Katgi, Abdullah) [1] ; Sevindik, ÖG (Sevindik, Omur Gokmen) [1] ; Gökbulut, AA (Gokbulut, Aysun Adan) [2] ; Özsan, GH (Ozsan, Guner Hayri) [1] ; Yüksel, F (Yuksel, Faize) [1] ; Solmaz, SM (Solmaz, Serife Medeni) [1] ; Alacacioglu, I (Alacacioglu, Inci) [1] ; Özcan, MA (Ozcan, Mehmet Ali) [1] ; Demirkan, F (Demirkan, Fatih) [1] ; Baran, Y (Baran, Yusuf) [2] ;

(provided by Clarivate)

Source

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS

Volume

Issue

Page

678-683

DOI

10.1177/1076029614550817

Published

OCT 2015

Indexed

2015-09-30

Document Type

Article

Abstract

Background: There have been concerns about the possible prothrombotic effects of nilotinib, especially in patients having cardiovascular risk factors. The potential mechanism behind the increased risk of thromboembolic events is still not clear.

Objectives: In this study, we aimed to evaluate possible harmful effects of nilotinib on endothelial cells. To this aim, we examined proliferative capacity and secretory functions of healthy human carotid artery endothelial cells (HCtAECs) in response to nilotinib.

Methods: 3-(4,5-Dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) cell proliferation method was used to determine antiproliferative effects of nilotinib on HCtAECs. The HCtAECs were incubated with 5, 10, and 100 nmol/L doses of nilotinib for 72 hours. Then, in order to assess the endothelial function, levels of nitric oxide (NO), von Willebrand factor (vWF), tissue plasminogen activator, plasminogen activator inhibitor 1 (PAI-1), and endothelin 1 (ET-1) were evaluated using enzyme-linked immunosorbent assay from tissue culture supernatants.

Results: There were slight but statistically significant decreases in cell proliferation in response to nilotinib. Nilotinib increased the secretion of t-PA, PAI-1, and vWF in a dose-dependent manner when compared with the untreated control group. The ET-1 secretion was lower in 5 nmol/L and higher in 10 and 100 nmol/L nilotinib-treated cells as compared to untreated cells. Regarding NO secretion, lower levels were observed in 5 and 10 nmol/L, and higher levels were detected in 100 nmol/L nilotinib-treated cells as compared to untreated control group cells.

Conclusion: Considering the results obtained in our study, nilotinib does not affect the functions of endothelial cells either in a prothrombotic or an antithrombotic fashion, despite a dose-dependent decline in cell viability.

Keywords

Author Keywords

nilotinib endothelial cells carotid artery function cell viability

Successful hematopoietic engraftment with gray platelets after allogeneic hematopoietic stem cell transplantation from gray platelet syndrome donor

Katgi, A (Katgi, Abdullah) [1] ; Ataca, P (Ataca, Pinar) [2] ; Kahraman, S (Kahraman, Selda) [1] ; Sevindik, OG (Sevindik, Omur Gokmen) [1] ; Sonmez, U (Sonmez, Ulker) [3] ; Solmaz, SM (Solmaz, Serife Medeni) [1] ; Piskin, O (Piskin, Ozden) [1] ; Demirkan, F (Demirkan, Fatih) [1] ; Ozsan, GH (Ozsan, Guner Hayri) [1]

(provided by Clarivate)

Source

BLOOD COAGULATION & FIBRINOLYSIS

Volume

Issue

Page

208-210

DOI

10.1097/MBC.0b013e32835aefc2

Published

MAR 2013

Indexed

2013-03-06

Document Type

Article

Abstract

Gray platelet syndrome (GPS) is a rare inherited disorder characterized by the absence of alpha-granules and their constituents. It may be present with thrombocytopenia and bleeding tendency. Platelets have a large and gray appearance under light and electron microscope. A 19-year old female patient with her second relapse acute lymphoblastic leukemia had to be consolidated with allohematopoietic stem cell transplantation (HSCT) after achieving remission with induction chemotherapy. The only available and one mismatch compatible donor was her brother, who was previously diagnosed as GPS. Allogeneic HSCT was performed from her brother in spite of GPS, and successful neutrophil and platelet engraftment achieved at the 12th and 42nd day of reinfusion, consecutively. The engrafted and circulating thrombocytes were large and gray and had little or no a-granules under electron microscope. The patient was well with no major bleeding event and increased need for thrombocyte replacement until developing bronchiolitis obliterans organizing pneumonia and respiratory distress syndrome. Thereafter death occurred. This is the first case of successful thrombocyte engraftment with documented gray thrombocyte megakaryopoiesis after allogeneic HSCT from a GPS donor. The only noteworthy issue was the slight prolongation of engraftment. Blood Coagul Fibrinolysis 24:208-210 (C) 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins.

Keywords

Author Keywords

allogeneic hematopoietic stem cell transplantation gray platelet syndrome

Coexistence of disseminated granuloma annulare and asymptomatic multiple myeloma

Aktan, S (Aktan, Sebnem) [1] ; Akarsu, S (Akarsu, Sevgi) [1] ; Avci, CC (Avci, Ceylan Canbaz) [1] ; Lebe, B (Lebe, Banu) [2] ; Katgi, A (Katgi, Abdullah) [3] ; Özsan, GH (Ozsan, Guner Hayri) [3]

(provided by Clarivate)

Source

TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY

Volume

Issue

Page

176-179

DOI

10.4274/turkderm.86094

Published

SEP 2013

Indexed

2013-09-01

Document Type

Article

Abstract

Granuloma annulare (GA), which is characterized by necrobiotic dermal papules, is a benign inflammatory dermatosis of unknown cause. Several morphologic forms of GA, including localized, disseminated, linear, nodular, perforating, subcutaneous, pustular, and arcuate dermal erythema have been reported in the literature. Disseminated GA, a rarely seen form, has been reported to be in association with some hematopoietic and solid malignancies, however, it has been suggested that the exact causative relationship between malignancy and GA is unclear. We present here a 66-year-old female patient with disseminated GA associated with asymptomatic multiple myeloma.

Keywords

Author Keywords

Granuloma annulare malignancy multiple myeloma

Prognostic significance of immunohistochemical classification of diffuse large B-cell lymphoma

Alacacioglu, I (Alacacioglu, Inci) [1] ; Ozcan, MA (Ozcan, Mehmet Ali) [1] ; Ozkal, S (Ozkal, Sermin) [2] ; Piskin, O (Piskin, Ozden) [1] ; Turgut, N (Turgut, Nurhilal) [1] ; Demirkan, F (Demirkan, Fatih) [1] ; Ozsan, GH (Ozsan, Guner Hayri) [1] ; Kargi, A (Kargi, Aydanur) [2] ; Undar, B (Undar, Bulent) [1]

(provided by Clarivate)

Source

HEMATOLOGY

Volume

Issue

Page

84-89

DOI

10.1179/102453309X385205

Published

APR 2009

Indexed

2009-04-01

Document Type

Article

Abstract

Aim: To evaluate the clinical significance of immunoperoxidase staining for CD10, bcl-6, mum-1 and bcl-2 to subdivide DLBCL into prognostic subgroups, we analysed 50 DLBCL cases using immunohistochemical methods.

Methods and results: Fifty DLBCL patients were evaluated retrospectively. The expression of CD10 was associated with better OS (p=0.04) whereas expression of mum-1 was associated with worse OS (p=0.009). There were no significance of OS in case of expression of bcl-6 (p=0.05) and bcl-2 (p=0.3). They were subclassified using CD10, mum-1, bcl-6 as germinal center B-cell like (GCB) lymphoma (30%) and non-GCB lymphoma (70%). The OS and EFS (event free survival) were longer in GCB group (p=0.002) and 5-year OS for GCB group was 92% compared with only 44% for the non-GCB group (p=0.02). The OS of the GCB group also was longer compared to that of the non-GCB group in low IPI subgroup (p=0.01).

Conclusion: The existance of survival differences between GCB a non-GCB group also in the patients with low IPI score, showed the importance of prognostic classification in the risk-adaptive treatment approaches. The classification as GCB and non-GCB based immunostains may enable to define more accurate prognostic groups in DLBCL.

Keywords

Lymphoma prognosis CD10 bcl-6 mum-1 bcl-2

Serum free light chain analysis in multiple myeloma and plasma cell dyscrasias

Ozsan, GH (Ozsan, Guner Hayri) [2] ; Dispenzieri, A (Dispenzieri, Angela) [1]

(provided by Clarivate)

Source

EXPERT REVIEW OF CLINICAL IMMUNOLOGY

Volume

Issue

Page

65-73

DOI

10.1586/ECI.10.80

Published

JAN 2011

Indexed

2011-01-01

Document Type

Review

Abstract

After the development of a reliable method to detect free light chains in serum, several investigations have been conducted to explore their importance in plasma cell dyscrasias (PCD). Detection of monoclonal proteins is very important in the diagnosis and management of PCD, which include a broad spectrum of diseases such as multiple myeloma and also benign, premalignant disorders like monoclonal gammopathy of undetermined significance. The aim of this article is to summarize the recent studies and to highlight the importance of free light chain analysis in the diagnosis of PCD, its prognostic value and role in the management of this group of diseases.

Keywords

Author Keywords

free light chain immunoglobulin multiple myeloma plasma cell disorders

Fatal Disseminated Mucormycosis In A Patient With Mantle Cell non-Hodgkin's Lymphoma: An Autopsy Case

Alacacioglu, I (Alacacioglu, Inci) [1] ; Kargi, A (Kargi, Aydanur) [2] ; Ozcan, MA (Ozcan, Mehmet Ali) ; Piskin, O (Piskin, Ozden) ; Solak, C (Solak, Cilem) ; Secil, M (Secil, Mustafa) [3] ; Unlu, M (Unlu, Mehtat) [2] ; Demirkan, F (Demirkan, Fatih) ; Ozsan, GH (Ozsan, Guner Hayri) ; Undar, B (Undar, Bulent)

(provided by Clarivate)

Source

BRAZILIAN JOURNAL OF INFECTIOUS DISEASES

Volume

Issue

Page

238-241

DOI

10.1590/S1413-86702009000300017

Published

JUN 2009

Indexed

2009-06-01

Document Type

Article

Abstract

A patient with mantle cell non-Hodgkin's lymphoma presented herself with fever, nausea, right upper quadrant pain on the 7th day of R-CHOP chemotherapy. After hospitalization with the suspicion of acute cholecystitis, she received antibiotherapy with G-CSF because of emerging neutropenia at the 10th day of chemotherapy. Abdominal computed tomography revealed small infarcts in the spleen and kidneys. The echymotic lesion which developed on her right lateral malleolus, became bullous in the following days and treated as ecthyma gangrenosum. Altough the patient was afebrile with a normal neutrophil count on the third day of antibiotherapy, she developed acute renal failure and deteriorated rapidly. The patient underwent hemodialysis but expired on the 10th day of hospitalization. Post mortem autopsy findings showed ischemic infarction and necrosis of parenchyma due to mycotic thrombosis of arteries and veins of many organs (heart, lung, diaphgram, kidneys, spleen, gut mucosa) as well as invasion of vessel walls and parenchyma by mucor. We reviewed mucormycosis in the light of this case.

Keywords

Author Keywords

Mucormycosis lymphoma autopsy

Occurrence in a Case of Philadelphia Negative Acute Lymphoblastic Leukemia following Treatment for Ewing's Sarcoma

Katgi, A (Katgi, Abdullah) [1] ; Kahraman, S (Kahraman, Selda) [1] ; Ataca, P (Ataca, Pinar) [2] ; Piskin, Ö (Piskin, Ozden) [1] ; Özcan, MA (Ozcan, Mehmet Ali) [1] ; Özsan, GH (Ozsan, Guner Hayri) [1] ; Demirkan, F (Demirkan, Fatih) [1] ; Ündar, B (Undar, Bulent) [1]

(provided by Clarivate)

Source

MARMARA MEDICAL JOURNAL

Volume

Issue

Page

100-102

DOI

10.5472/MMJ.2012.02158.1

Published

2012

Indexed

2012-01-01

Document Type

Article

Abstract

Therapy-related leukemias are 10-20% of all acute leukemia cases. Therapy-related acute lymphoblastic leukemia (ALL) is less frequent than therapy-related acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). In this paper, we present a patient with Ewing's sarcoma (ES) in the soft tissue of his right breast cured by chemotherapy and radiotherapy. He developed Ph(-) ALL four years following the therapy.

Keywords

Author Keywords

Ph(-) ALL Secondary leukemia Ewing's sarcoma

Plasma thrombin activatable fibrinolysis inhibitor levels in Behcet's disease

Özcan, MA (Ozcan, Mehmet Ali) [1] ; Akar, S (Akar, Servet) [2] ; Alacacioglu, I (Alacacioglu, Inci) [1] ; Piskin, O (Piskin, Ozden) [1] ; Yüksel, F (Yuksel, Faize) [1] ; Gürler, O (Gurler, Oguz) [2] ; Akkoç, N (Akkoc, Nurullah) [2] ; Demirkan, F (Demirkan, Fatih) [1] ; Özsan, GH (Ozsan, Guner Hayri) [1] ; Özkan, S (Ozkan, Sebnem) [3] ;

(provided by Clarivate)

Source

TURKISH JOURNAL OF MEDICAL SCIENCES

Volume

Issue

Page

267-271

Published

OCT 2007

Indexed

2007-10-01

Document Type

Article

Abstract

Aim: The precise pathogenetic mechanisms causing thrombotic complications in Behcet's disease (BID) are still not known. To explain the pathogenesis with coagulation induction or a defective fibrinolysis superimposed on endothelial dysfunction, various hemostatic parameters were studied. Thrombin activatable fibrinolysis inhibitor (TAFI), downregulating plasmin generation and fibrinolysis, is a novel risk factor for thrombotic disorders. We studied plasma TAR levels in BD in comparison with healthy controls.

Materials and Methods: Twenty-three patients with BD (mean age: 38.3 +/- 10.83, M/F: 5/18) diagnosed according to the criteria of the International Study Group and 20 healthy volunteers (mean age: 38.05 +/- 6.29, M/F: 9/11) were enrolled in this study. Patients with liver or renal disease, diabetes mellitus, coronary artery disease, hemophilia, antiphospholipid antibody positivity or using oral contraceptive drugs were excluded from the study. Plasma TAFI levels were determined by using an ELISA test.

Results: The mean TAFI antigen levels were 8.40 +/- 1.81 mu g/ml in BID patients and 7.30 +/- 0.64 mu g/ml in healthy volunteers. A statistically significant difference was found between TAFI antigen levels of these two groups (P = 0.01).

Conclusions: TAR antigen levels were found to be increased in BID, regardless of thrombotic events. To clarify the exact role of TAFI in thrombotic complications of the disease, future studies including more patients with and without thrombosis are needed.

Keywords

Behcet's disease TAF I fibrinolysis coagulation

Sayfa içeriği güncellenmektedir.

İçeriğin Devamı İçin Tıklayın